LSD explained

Watchedfields:changed
Verifiedrevid:629704081
Drug Name:Lysergic acid diethylamide
Inn:Lysergide
Iupac Name:(6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-''fg'']quinoline-9-carboxamide
Drugs.Com:Reference
Pregnancy Us:C
Pregnancy Category:C
Tradename:Delysid
Legal Au:Schedule 9
Legal Br:F2
Legal Ca:Schedule III
Legal Nz:Class A
Legal Uk:Class A
Legal Un:P I
Legal Us:Schedule I
Legal De:Anlage I
Addiction Liability:None
Legal Status:Illicit drug
Dependency Liability:Low[1]
Routes Of Administration:By mouth, under the tongue
Pronounce:pronounced as //daɪ eθəl ˈæmaɪd//, pronounced as //æmɪd//, or pronounced as //eɪmaɪd//[2] [3] [4]
Bioavailability:71%
Protein Bound:Unknown
Metabolism:Liver (CYP450)
Metabolites:2-Oxo-3-hydroxy-LSD
Onset:30–40 minutes[5]
Duration Of Action:8–20 hours[6]
Elimination Half-Life:3.6 hours
Excretion:Kidneys
Cas Number:50-37-3
Chebi:6605
Pubchem:5761
Iuphar Ligand:17
Drugbank:DB04829
Chemspiderid:5558
Unii:8NA5SWF92O
Kegg:C07542
Chembl:263881
Atc Prefix:None
Pdb Ligand:7LD
Class:Hallucinogen (psychedelic)
C:20
H:25
N:3
O:1
Smiles:CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4c3c(ccc4)C2=C1)C
Stdinchi:1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1
Stdinchikey:VAYOSLLFUXYJDT-RDTXWAMCSA-N
Synonyms:LSD, LSD-25, LAD, acid, lucy, among others
Melting Point:80
Melting High:85
Solubility:67.02[7]

Lysergic acid diethylamide, commonly known as LSD (from German German: Lysergsäure-diethylamid), and known colloquially as acid or lucy, is a potent psychedelic drug.[8] Effects typically include intensified thoughts, emotions, and sensory perception.[9] At sufficiently high dosages, LSD manifests primarily mental, visual, and auditory hallucinations.[10] [11] Dilated pupils, increased blood pressure, and increased body temperature are typical.

Effects typically begin within half an hour and can last for up to 20 hours (although on average, experiences last 8–12 hours).[12] LSD is also capable of causing mystical experiences and ego dissolution.[13] It is used mainly as a recreational drug or for spiritual reasons.[14] [15] LSD is both the prototypical psychedelic and one of the "classical" psychedelics, being the psychedelic with the greatest scientific and cultural significance. LSD is synthesized as a solid compound, typically in the form of a powder or a crystalline material. This solid LSD is then dissolved in a liquid solvent, such as ethanol or distilled water, to create a solution. The liquid serves as a carrier for the LSD, allowing for accurate dosage and administration onto small pieces of blotter paper called tabs. LSD is typically either swallowed or held under the tongue. In pure form, LSD is clear or white in color, has no smell, and is crystalline. It breaks down with exposure to ultraviolet light.

LSD is pharmacologically considered to be non-addictive with a low potential for abuse. Adverse psychological reactions are possible, such as anxiety, paranoia, and delusions.[16] In rare cases, LSD can induce "flashbacks", known as hallucinogen persisting perception disorder, in which a person experiences apparent lasting or persistent visual hallucinations or perceptual distortions, such as visual snow and palinopsia.[17]

LSD is structurally related to substituted tryptamines, a class of compounds that includes psilocybin, the active compound found in psychedelic mushrooms. Thus, LSD shares some mechanisms of action and psychedelic effects with psilocybin and other tryptamines.[18] [19] [20]

The effects of LSD are thought to stem primarily from it being an agonist at the 5-HT2A serotonin receptor. While exactly how LSD exerts its effects by agonism at this receptor is not fully understood, corresponding increased glutamatergic neurotransmission and reduced default mode network activity are thought to be key mechanisms of action.[16] [8] [21] [22] [23] LSD also binds to dopamine D1 and D2 receptors, which is thought to contribute to reports of LSD being more stimulating than compounds such as psilocybin.

Swiss chemist Albert Hofmann first synthesized LSD in 1938 from lysergic acid, a chemical derived from the hydrolysis of ergotamine, an alkaloid found in ergot, a fungus that infects grain.[24] LSD was the 25th of various lysergamides Hofmann synthesized from lysergic acid while trying to develop a new analeptic, hence the alternate name LSD-25. Hofmann discovered its effects in humans in 1943, after unintentionally ingesting an unknown amount, possibly absorbing it through his skin.[25] [26] [27] LSD was subject to exceptional interest within the field of psychiatry in the 1950s and early 1960s, with Sandoz distributing LSD to researchers under the trademark name Delysid in an attempt to find a marketable use for it.

LSD-assisted psychotherapy was used in the 1950s and early 1960s by psychiatrists such as Humphry Osmond, who pioneered the application of LSD to the treatment of alcoholism, with promising results.[26] [28] [29] [30] Osmond coined the term "psychedelic" (lit. mind manifesting) as a term for LSD and related hallucinogens, superseding the previously held "psychotomimetic" model in which LSD was believed to mimic schizophrenia. In contrast to schizophrenia, LSD can induce transcendent experiences, or mental states that transcend the experience of everyday consciousness, with lasting psychological benefit. During this time, the Central Intelligence Agency (CIA) began using LSD in the research project Project MKUltra, which used psychoactive substances to aid interrogation. The CIA administered LSD to unwitting test subjects in order to observe how they would react, the most well-known example of this being Operation Midnight Climax. LSD was one of several psychoactive substances evaluated by the U.S. Army Chemical Corps as possible non-lethal incapacitants in the Edgewood Arsenal human experiments.

In the 1960s, LSD and other psychedelics were adopted by, and became synonymous with, the counterculture movement due to their perceived ability to expand consciousness. This resulted in LSD being viewed as a cultural threat to American values and the Vietnam war effort, and it was designated as a Schedule I (illegal for medical as well as recreational use) substance in 1968.[31] It was listed as a Schedule 1 controlled substance by the United Nations in 1971 and currently has no approved medical uses., about 10% of people in the United States have used LSD at some point in their lives, while 0.7% have used it in the last year.[32] It was most popular in the 1960s to 1980s. The use of LSD among US adults increased 56.4% from 2015 to 2018.[33]

Uses

Recreational

LSD is commonly used as a recreational drug.[34]

Spiritual

LSD can catalyze intense spiritual experiences and is thus considered an entheogen. Some users have reported out of body experiences. In 1966, Timothy Leary established the League for Spiritual Discovery with LSD as its sacrament.[35] [36] Stanislav Grof has written that religious and mystical experiences observed during LSD sessions appear to be phenomenologically indistinguishable from similar descriptions in the sacred scriptures of the great religions of the world and the texts of ancient civilizations.[37]

Medical

LSD currently has no approved uses in medicine.[38] [39] A meta analysis concluded that a single dose was shown to be effective at reducing alcohol consumption in people suffering from alcoholism.[30] LSD has also been studied in depression, anxiety,[40] [41] and drug dependence, with positive preliminary results.[42] [43]

Effects

LSD is exceptionally potent, with as little as 20 μg capable of producing a noticeable effect.

Physical

LSD can induce physical effects such as pupil dilation, decreased appetite, increased sweating, and wakefulness. The physical reactions to LSD vary greatly and some may be a result of its psychological effects. Commonly observed symptoms include increased body temperature, blood sugar, and heart rate, as well as goose bumps, jaw clenching, dry mouth, and hyperreflexia. In cases of adverse reactions, users may experience numbness, weakness, nausea, and tremors.

Psychological

The primary immediate psychological effects of LSD are visual hallucinations and illusions, often referred to as "trips". These effects typically begin within 20–30 minutes of oral ingestion, peak three to four hours after ingestion, and can last up to 20 hours, particularly with higher doses. An "afterglow" effect, characterized by an improved mood or perceived mental state, may persist for days or weeks following ingestion.[44] Positive experiences, or "good trips", are described as intensely pleasurable and can include feelings of joy, euphoria, an increased appreciation for life, decreased anxiety, a sense of spiritual enlightenment, and a feeling of interconnectedness with the universe.[45] [46]

Conversely, negative experiences, known as "bad trips," can induce feelings of fear, anxiety, panic, paranoia, and even suicidal ideation. While the occurrence of a bad trip is unpredictable, factors such as mood, surroundings, sleep, hydration, and social setting, collectively referred to as "set and setting", can influence the risk and are considered important in minimizing the likelihood of a negative experience.

Sensory

LSD induces an animated sensory experience affecting senses, emotions, memories, time, and awareness, lasting from 6 to 20 hours, with the duration dependent on dosage and individual tolerance. Effects typically commence within 30 to 90 minutes post-ingestion, ranging from subtle perceptual changes to profound cognitive shifts. Alterations in auditory and visual perception are common.[47]

Users may experience enhanced visual phenomena, such as vibrant colors, objects appearing to morph, ripple or move, and geometric patterns on various surfaces. Changes in the perception of food's texture and taste are also noted, sometimes leading to aversion towards certain foods.[48] [49]

There are reports of inanimate objects appearing animated, with static objects seeming to move in additional spatial dimensions.[50] The auditory effects of LSD may include echo-like distortions of sounds. Basic visual effects often resemble phosphenes and can be influenced by concentration, thoughts, emotions, or music.[51] Auditory effects may include echo-like distortions and an intensified experience of music. Higher doses can lead to more intense sensory perception alterations, including synesthesia, perception of additional dimensions, and temporary dissociation.

Adverse effects

LSD, a classical psychedelic, is deemed physiologically safe at standard dosages (50–200 μg) and its primary risks lie in psychological effects rather than physiological harm.[21] [52] A 2010 study by David Nutt ranked LSD as significantly less harmful than alcohol, placing it near the bottom of a list assessing the harm of 20 drugs.[53]

Psychological effects

Mental disorders

LSD can induce panic attacks or extreme anxiety, colloquially termed a "bad trip". Despite lower rates of depression and substance abuse found in psychedelic drug users compared to controls, LSD presents heightened risks for individuals with severe mental illnesses like schizophrenia.[54] These hallucinogens can catalyze psychiatric disorders in predisposed individuals, although they do not tend to induce illness in emotionally healthy people.[21]

Suggestibility

While research from the 1960s indicated increased suggestibility under the influence of LSD among both mentally ill and healthy individuals, recent documents suggest that the CIA and Department of Defense have discontinued research into LSD as a means of mind control.[55] [56] [57]

Flashbacks

Flashbacks are psychological episodes where individuals re-experience some of LSD's subjective effects after the drug has worn off, persisting for days or months post-hallucinogen use.[58] [59] These experiences are associated with hallucinogen persisting perception disorder (HPPD), where flashbacks occur intermittently or chronically, causing distress or functional impairment.[17]

The etiology of flashbacks is varied. Some cases are attributed to somatic symptom disorder, where individuals fixate on normal somatic experiences previously unnoticed prior to drug consumption.[60] Other instances are linked to associative reactions to contextual cues, similar to responses observed in individuals with past trauma or emotional experiences.[61] The risk factors for flashbacks remain unclear, but pre-existing psychopathologies may be significant contributors.[62]

Estimating the prevalence of HPPD is challenging. It is considered rare, with occurrences ranging from 1 in 20 users experiencing the transient and less severe type 1 HPPD, to 1 in 50,000 for the more concerning type 2 HPPD.[17] Contrary to internet rumors, LSD is not stored long-term in the spinal cord or other body parts. Pharmacological evidence indicates LSD has a half-life of 175 minutes and is metabolized into water-soluble compounds like 2-oxo-3-hydroxy-LSD, eliminated through urine without evidence of long-term storage.[16] Clinical evidence also suggests that chronic use of SSRIs can potentiate LSD-induced flashbacks, even months after stopping LSD use.[63]

Drug-interactions

Several psychedelics, including LSD, are metabolized by CYP2D6. Concurrent use of SSRIs, potent inhibitors of CYP2D6, with LSD may heighten the risk of serotonin syndrome.[63] Chronic usage of SSRIs, TCAs, and MAOIs is believed to diminish the subjective effects of psychedelics, likely due to SSRI-induced 5-HT2A receptor downregulation and MAOI-induced 5-HT2A receptor desensitization.[16] [63] Interactions between psychedelics and antipsychotics or anticonvulsants are not well-documented; however, co-use with mood stabilizers like lithium may induce seizures and dissociative effects, particularly in individuals with bipolar disorder.[63] [64] [65] Lithium notably intensifies LSD reactions, potentially leading to acute comatose states when combined.

Fatal dose

Lethal oral dose of LSD in humans is estimated at 100 mg, based on LD50 and lethal blood concentrations observed in rodent studies.

Tolerance

LSD shows significant tachyphylaxis, with tolerance developing 24 hours after administration. The progression of tolerance at intervals shorter than 24 hours remains largely unknown.[66] Tolerance typically resets to baseline after 3–4 days of abstinence.[67] [68] Cross-tolerance occurs between LSD, mescaline, psilocybin,[69] [70] and to some degree DMT. Tolerance to LSD also builds up with consistent use,[71] and is believed to result from serotonin 5-HT2A receptor downregulation. Researchers believe that tolerance returns to baseline after two weeks of not using psychedelics.[72]

Addiction and dependence liability

The NIH states that LSD is addictive,[24] while most other sources state it is not.[52] [73] A 2009 textbook states that it "rarely produce[s] compulsive use."[74] A 2006 review states it is readily abused, but does not result in addiction.[73] There are no recorded successful attempts to train animals to self-administer LSD in laboratory settings.[21] A study reports that although tolerance to LSD builds up rapidly, a withdrawal syndrome does not appear, suggesting that a potential syndrome does not necessarily relate to the possibility of acquiring rapid tolerance to a substance.[75] A report examining substance use disorder for DSM-IV noted that almost no hallucinogens produced dependence, unlike psychoactive drugs of other classes such as stimulants and depressants.[76] [77]

Cancer and pregnancy

The mutagenic potential of LSD is unclear. Overall, the evidence seems to point to limited or no effect at commonly used doses.[78] Studies showed no evidence of teratogenic or mutagenic effects.[16]

Overdose

There have been no documented fatal human overdoses from LSD,[16] [79] although there has been no "comprehensive review since the 1950s" and "almost no legal clinical research since the 1970s".[16] Eight individuals who had accidentally consumed an exceedingly high amount of LSD, mistaking it for cocaine, and had gastric levels of 1000–7000 μg LSD tartrate per 100 mL and blood plasma levels up to 26 μg/ml, had suffered from comatose states, vomiting, respiratory problems, hyperthermia, and light gastrointestinal bleeding; however, all of them survived without residual effects upon hospital intervention.[16] [80]

Individuals experiencing a bad trip after LSD intoxication may be presented with severe anxiety, tachycardia, often accompanied by phases of psychotic agitation and varying degrees of delusions. Cases of death on a bad trip have been reported due to prone maximal restraint (commonly known as a hogtie) and positional asphyxia when the individuals were restrained by law enforcement personnel.

Massive doses are largely managed by symptomatic treatments, and agitation can be addressed with benzodiazepines.[81] Reassurance in a calm, safe environment is beneficial.[82] Antipsychotic agents such as neuroleptics and haloperidol are not recommended as they may have adverse psychotomimetic effects. Gastrointestinal decontamination with activated charcoal is of little use due to the rapid absorption of LSD, unless done within 30–60 minutes of ingesting exceedingly huge amounts. Administration of anticoagulants, vasodilators, and sympatholytics may be useful for treating ergotism.

Designer drug overdose

Many novel psychoactive substances of 25-NB (NBOMe) series, such as 25I-NBOMe and 25B-NBOMe, are regularly sold as LSD in blotter papers.[83] [84] NBOMe compounds are often associated with life-threatening toxicity and death.[83] [85] Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD,[86] and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently".[79] Researchers state that the alleged physiological toxicity of LSD is likely due to psychoactive substances other than LSD.[52] NBOMe compounds are reported to have a bitter taste,[79] and are not active orally, and are usually taken sublingually.[87] When NBOMes are administered sublingually, numbness of the tongue and mouth followed by a metallic chemical taste was observed, and researchers describe this physical side effect as one of the main discriminants between NBOMe compounds and LSD.[88] [89] [90] Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity, but NBOMe compounds have extremely different safety profiles.[79] [85] Ehrlich's reagent can be used to test for the presence of LSD.

Pharmacology

Pharmacodynamics

Most serotonergic psychedelics are not significantly dopaminergic, and LSD is therefore atypical in this regard. The agonism of the D2 receptor by LSD may contribute to its psychoactive effects in humans.[91]

LSD binds to most serotonin receptor subtypes except for the 5-HT3 and 5-HT4 receptors. However, most of these receptors are affected at too low affinity to be sufficiently activated by the brain concentration of approximately 10–20 nM.[21] In humans, recreational doses of LSD can affect 5-HT1A (Ki = 1.1 nM), 5-HT2A (Ki = 2.9 nM), 5-HT2B (Ki = 4.9 nM), 5-HT2C (Ki = 23 nM), 5-HT5A (Ki = 9 nM [in cloned rat tissues]), and 5-HT6 receptors (Ki = 2.3 nM). Although not present in humans, 5-HT5B receptors found in rodents also have a high affinity for LSD.[92] The psychedelic effects of LSD are attributed to cross-activation of 5-HT2A receptor heteromers.[93] Many but not all 5-HT2A agonists are psychedelics and 5-HT2A antagonists block the psychedelic activity of LSD. LSD exhibits functional selectivity at the 5-HT2A and 5-HT2C receptors in that it activates the signal transduction enzyme phospholipase A2 instead of activating the enzyme phospholipase C as the endogenous ligand serotonin does.[94]

Exactly how LSD produces its effects is unknown, but it is thought that it works by increasing glutamate release in the cerebral cortex[21] and therefore excitation in this area, specifically in layer V.[95] LSD, like many other drugs of recreational use, has been shown to activate DARPP-32-related pathways.[96] The drug enhances dopamine D2 receptor protomer recognition and signaling of D2–5-HT2A receptor complexes,[97] which may contribute to its psychotropic effects. LSD has been shown to have low affinity for H1 receptors, displaying antihistamine effects.[98]

LSD is a biased agonist that induces a conformation in serotonin receptors that preferentially recruits β-arrestin over activating G proteins.[99] LSD also has an exceptionally long residence time when bound to serotonin receptors lasting hours, consistent with the long lasting effects of LSD despite its relatively rapid clearance. A crystal structure of 5-HT2B bound to LSD reveals an extracellular loop that forms a lid over the diethylamide end of the binding cavity which explains the slow rate of LSD unbinding from serotonin receptors.[100] The related lysergamide lysergic acid amide (LSA) that lacks the diethylamide moiety is far less hallucinogenic in comparison.

Pharmacokinetics

The acute effects of LSD normally last between 6 and 10 hours depending on dosage, tolerance, and age.[101] [102] Aghajanian and Bing (1964) found LSD had an elimination half-life of only 175 minutes (about 3 hours).[103] However, using more accurate techniques, Papac and Foltz (1990) reported that 1 μg/kg oral LSD given to a single male volunteer had an apparent plasma half-life of 5.1 hours, with a peak plasma concentration of 5 ng/mL at 3 hours post-dose.[104]

The pharmacokinetics of LSD were not properly determined until 2015, which is not surprising for a drug with the kind of low-μg potency that LSD possesses. In a sample of 16 healthy subjects, a single mid-range 200 μg oral dose of LSD was found to produce mean maximal concentrations of 4.5 ng/mL at a median of 1.5 hours (range 0.5–4 hours) post-administration. Concentrations of LSD decreased following first-order kinetics with a half-life of 3.6±0.9 hours and a terminal half-life of 8.9±5.9 hours.

The effects of the dose of LSD given lasted for up to 12 hours and were closely correlated with the concentrations of LSD present in circulation over time, with no acute tolerance observed. Only 1% of the drug was eliminated in urine unchanged, whereas 13% was eliminated as the major metabolite 2-oxo-3-hydroxy-LSD (O-H-LSD) within 24 hours. O-H-LSD is formed by cytochrome P450 enzymes, although the specific enzymes involved are unknown, and it does not appear to be known whether O-H-LSD is pharmacologically active or not. The oral bioavailability of LSD was crudely estimated as approximately 71% using previous data on intravenous administration of LSD. The sample was equally divided between male and female subjects and there were no significant sex differences observed in the pharmacokinetics of LSD.

Mechanisms of action

Neuroimaging studies using resting state fMRI recently suggested that LSD changes the cortical functional architecture.[105] These modifications spatially overlap with the distribution of serotoninergic receptors. In particular, increased connectivity and activity were observed in regions with high expression of 5-HT2A receptor, while a decrease in activity and connectivity was observed in cortical areas that are dense with 5-HT1A receptor.[106] Experimental data suggest that subcortical structures, particularly the thalamus, play a synergistic role with the cerebral cortex in mediating the psychedelic experience. LSD, through its binding to cortical 5-HT2A receptor, may enhance excitatory neurotransmission along frontostriatal projections and, consequently, reduce thalamic filtering of sensory stimuli towards the cortex.[107] This phenomenon appears to selectively involve ventral, intralaminar, and pulvinar nuclei.[107]

Chemistry

LSD is a chiral compound with two stereocenters at the carbon atoms C-5 and C-8, so that theoretically four different optical isomers of LSD could exist. LSD, also called (+)-d-LSD,[108] has the absolute configuration (5R,8R). 5S stereoisomers of lysergamides do not exist in nature and are not formed during the synthesis from d-lysergic acid. Retrosynthetically, the C-5 stereocenter could be analysed as having the same configuration of the alpha carbon of the naturally occurring amino acid L-tryptophan, the precursor to all biosynthetic ergoline compounds.

However, LSD and iso-LSD, the two C-8 isomers, rapidly interconvert in the presence of bases, as the alpha proton is acidic and can be deprotonated and reprotonated. Non-psychoactive iso-LSD which has formed during the synthesis can be separated by chromatography and can be isomerized to LSD.

Pure salts of LSD are triboluminescent, emitting small flashes of white light when shaken in the dark. LSD is strongly fluorescent and will glow bluish-white under UV light.

Synthesis

LSD is an ergoline derivative. It is commonly synthesized by reacting diethylamine with an activated form of lysergic acid. Activating reagents include phosphoryl chloride[109] and peptide coupling reagents.[110] Lysergic acid is made by alkaline hydrolysis of lysergamides like ergotamine, a substance usually derived from the ergot fungus on agar plate; or, theoretically possible, but impractical and uncommon, from ergine (lysergic acid amide, LSA) extracted from morning glory seeds.[111] Lysergic acid can also be produced synthetically, although these processes are not used in clandestine manufacture due to their low yields and high complexity.[112] [113]

Research

The precursor for LSD, lysergic acid, has been produced by GMO baker's yeast.[114]

Dosage

A single dose of LSD may be between 40 and 500 micrograms—an amount roughly equal to one-tenth the mass of a grain of sand. Threshold effects can be felt with as little as 25 micrograms of LSD.[115] [116] The practice of using sub-threshold doses is called microdosing.[117] Dosages of LSD are measured in micrograms (μg), or millionths of a gram.

In the mid-1960s, the most important black market LSD manufacturer (Owsley Stanley) distributed LSD at a standard concentration of 270 μg,[118] while street samples of the 1970s contained 30 to 300 μg. By the 1980s, the amount had reduced to between 100 and 125 μg, dropping more in the 1990s to the 20–80 μg range,[119] and even more in the 2000s (decade).[120]

Reactivity and degradation

"LSD," writes the chemist Alexander Shulgin, "is an unusually fragile molecule ... As a salt, in water, cold, and free from air and light exposure, it is stable indefinitely."

LSD has two labile protons at the tertiary stereogenic C5 and C8 positions, rendering these centers prone to epimerisation. The C8 proton is more labile due to the electron-withdrawing carboxamide attachment, but removal of the chiral proton at the C5 position (which was once also an alpha proton of the parent molecule tryptophan) is assisted by the inductively withdrawing nitrogen and pi electron delocalisation with the indole ring.

LSD also has enamine-type reactivity because of the electron-donating effects of the indole ring. Because of this, chlorine destroys LSD molecules on contact; even though chlorinated tap water contains only a slight amount of chlorine, the small quantity of compound typical to an LSD solution will likely be eliminated when dissolved in tap water. The double bond between the 8-position and the aromatic ring, being conjugated with the indole ring, is susceptible to nucleophilic attacks by water or alcohol, especially in the presence of UV or other kinds of light. LSD often converts to "lumi-LSD," which is inactive in human beings.

A controlled study was undertaken to determine the stability of LSD in pooled urine samples.[121] The concentrations of LSD in urine samples were followed over time at various temperatures, in different types of storage containers, at various exposures to different wavelengths of light, and at varying pH values. These studies demonstrated no significant loss in LSD concentration at 25 °C for up to four weeks. After four weeks of incubation, a 30% loss in LSD concentration at 37 °C and up to a 40% at 45 °C were observed. Urine fortified with LSD and stored in amber glass or nontransparent polyethylene containers showed no change in concentration under any light conditions. Stability of LSD in transparent containers under light was dependent on the distance between the light source and the samples, the wavelength of light, exposure time, and the intensity of light. After prolonged exposure to heat in alkaline pH conditions, 10 to 15% of the parent LSD epimerized to iso-LSD. Under acidic conditions, less than 5% of the LSD was converted to iso-LSD. It was also demonstrated that trace amounts of metal ions in buffer or urine could catalyze the decomposition of LSD and that this process can be avoided by the addition of EDTA.

Detection

LSD can be detected in concentrations larger than approximately 10% in a sample using Ehrlich's reagent and Hofmann's reagent. However, detecting LSD in human tissues is more challenging due to its active dosage being significantly lower (in micrograms) compared to most other drugs (in milligrams).[122]

LSD may be quantified in urine for drug abuse testing programs, in plasma or serum to confirm poisoning in hospitalized victims, or in whole blood for forensic investigations. The parent drug and its major metabolite are unstable in biofluids when exposed to light, heat, or alkaline conditions, necessitating protection from light, low-temperature storage, and quick analysis to minimize losses.[123] Maximum plasma concentrations are typically observed 1.4 to 1.5 hours after oral administration of 100 μg and 200 μg, respectively, with a plasma half-life of approximately 2.6 hours (ranging from 2.2 to 3.4 hours among test subjects).[124]

Due to its potency in microgram quantities, LSD is often not included in standard pre-employment urine or hair analyses.[122] [125] However, advanced liquid chromatography–mass spectrometry methods can detect LSD in biological samples even after a single use.[125]

History

See main article: History of LSD. LSD was first synthesized on November 16, 1938[126] by Swiss chemist Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives. The abbreviation "LSD" is from the German "Lysergsäurediethylamid".[127]

LSD's psychedelic properties were discovered 5 years later when Hofmann himself accidentally ingested an unknown quantity of the chemical.[128] The first intentional ingestion of LSD occurred on April 19, 1943, when Hofmann ingested 250 μg of LSD. He said this would be a threshold dose based on the dosages of other ergot alkaloids. Hofmann found the effects to be much stronger than he anticipated.[129] Sandoz Laboratories introduced LSD as a psychiatric drug in 1947 and marketed LSD as a psychiatric panacea, hailing it "as a cure for everything from schizophrenia to criminal behavior, 'sexual perversions', and alcoholism."[130] Sandoz would send the drug for free to researchers investigating its effects.[25]

Beginning in the 1950s, the US Central Intelligence Agency (CIA) began a research program code named Project MKUltra. The CIA introduced LSD to the United States, purchasing the entire world's supply for $240,000 and propagating the LSD through CIA front organizations to American hospitals, clinics, prisons and research centers.[131] Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public in order to study their reactions, usually without the subjects' knowledge. The project was revealed in the US congressional Rockefeller Commission report in 1975.

In 1963, the Sandoz patents on LSD expired[119] and the Czech company Spofa began to produce the substance. Sandoz stopped the production and distribution in 1965.

Several figures, including Aldous Huxley, Timothy Leary, and Al Hubbard, had begun to advocate the consumption of LSD. LSD became central to the counterculture of the 1960s.[132] In the early 1960s the use of LSD and other hallucinogens was advocated by new proponents of consciousness expansion such as Leary, Huxley, Alan Watts and Arthur Koestler,[133] [134] and according to L. R. Veysey they profoundly influenced the thinking of the new generation of youth.[135]

On October 24, 1968, possession of LSD was made illegal in the United States.[136] The last FDA approved study of LSD in patients ended in 1980, while a study in healthy volunteers was made in the late 1980s. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993.[137]

In November 2020, Oregon became the first US state to decriminalize possession of small amounts of LSD after voters approved Ballot Measure 110.[138]

Society and culture

Counterculture

By the mid-1960s, the youth countercultures in California, particularly in San Francisco, had widely adopted the use of hallucinogenic drugs, including LSD. The first major underground LSD factory was established by Owsley Stanley.[139] Around this time, the Merry Pranksters, associated with novelist Ken Kesey, organized the Acid Tests, events in San Francisco involving LSD consumption, accompanied by light shows and improvised music.[140] [141] Their activities, including cross-country trips in a psychedelically decorated bus and interactions with major figures of the beat movement, were later documented in Tom Wolfe's The Electric Kool-Aid Acid Test (1968).[142]

In San Francisco's Haight-Ashbury neighborhood, the Psychedelic Shop was opened in January 1966 by brothers Ron and Jay Thelin to promote safe use of LSD. This shop played a significant role in popularizing LSD in the area and establishing Haight-Ashbury as the epicenter of the hippie counterculture. The Thelins also organized the Love Pageant Rally in Golden Gate Park in October 1966, protesting against California's ban on LSD.[143] [144]

A similar movement developed in London, led by British academic Michael Hollingshead, who first tried LSD in America in 1961. After experiencing LSD and interacting with notable figures such as Aldous Huxley, Timothy Leary, and Richard Alpert, Hollingshead played a key role in the famous LSD research at Millbrook before moving to New York City for his own experiments. In 1965, he returned to the UK and founded the World Psychedelic Center in Chelsea, London.[145]

Music and Art

The influence of LSD in the realms of music and art became pronounced in the 1960s, especially through the Acid Tests and related events involving bands like the Grateful Dead, Jefferson Airplane, and Big Brother and the Holding Company. San Francisco-based artists such as Rick Griffin, Victor Moscoso, and Wes Wilson contributed to this movement through their psychedelic poster and album art. The Grateful Dead, in particular, became central to the culture of "Deadheads," with their music heavily influenced by LSD.

In the United Kingdom, Michael Hollingshead, reputed for introducing LSD to various artists and musicians like Storm Thorgerson, Donovan, Keith Richards, and members of the Beatles, played a significant role in the drug's proliferation in the British art and music scene. Despite LSD's illegal status from 1966, it was widely used by groups including the Beatles, the Rolling Stones, and the Moody Blues. Their experiences influenced works such as the Beatles' Sgt. Pepper's Lonely Hearts Club Band and Cream's Disraeli Gears, featuring psychedelic-themed music and artwork.[146]

Psychedelic music of the 1960s often sought to replicate the LSD experience, incorporating exotic instrumentation, electric guitars with effects pedals, and elaborate studio techniques. Artists and bands utilized instruments like sitars and tablas, and employed studio effects such as backwards tapes, panning, and phasing.[147] [148] Songs such as John Prine's "Illegal Smile" and the Beatles' "Lucy in the Sky with Diamonds" have been associated with LSD, although the latter's authors denied such claims.[149] [150]

Contemporary artists influenced by LSD include Keith Haring in the visual arts,[151] various electronic dance music creators,[152] and the jam band Phish.[153] The 2018 Leo Butler play All You Need is LSD is inspired by the author's interest in the history of LSD.[154]

Legal status

The United Nations Convention on Psychotropic Substances of 1971 mandates that signing parties, including the United States, Australia, New Zealand, and most of Europe, prohibit LSD. Enforcement of these laws varies by country. The convention allows medical and scientific research with LSD.[155]

Australia

In Australia, LSD is classified as a Schedule 9 prohibited substance under the Poisons Standard (February 2017), indicating it may be abused or misused and its manufacture, possession, sale, or use should be prohibited except for approved research purposes.[156] In Western Australia, the Misuse of Drugs Act 1981 provides guidelines for possession and trafficking of substances like LSD.[157]

Canada

In Canada, LSD is listed under Schedule III of the Controlled Drugs and Substances Act. Unauthorized possession and trafficking of the substance can lead to significant legal penalties.[158]

United Kingdom

In the United Kingdom, LSD is a Class A drug under the Misuse of Drugs Act 1971, making unauthorized possession and trafficking punishable by severe penalties. The Runciman Report and Transform Drug Policy Foundation have made recommendations and proposals regarding the legal regulation of LSD and other psychedelics.[159] [160]

United States

In the United States, LSD is classified as a Schedule I controlled substance under the Controlled Substances Act of 1970, making its manufacture, possession, and distribution illegal without a DEA license. The law considers LSD to have a high potential for abuse, no legitimate medical use, and to be unsafe even under medical supervision. The US Supreme Court case Neal v. United States (1995) clarified the sentencing guidelines related to LSD possession.[161]

Oregon decriminalized personal possession of small amounts of drugs, including LSD, in February 2021, and California has seen legislative efforts to decriminalize psychedelics.[162]

Mexico

Mexico decriminalized the possession of small amounts of drugs, including LSD, for personal use in 2009. The law specifies possession limits and establishes that possession is not a crime within designated quantities.[163]

Czech Republic

In the Czech Republic, possession of "amount larger than small" of LSD is criminalized, while possession of smaller amounts is a misdemeanor. The definition of "amount larger than small" is determined by judicial practice and specific regulations.[164]

Economics

Production

An active dose of LSD is very minute, allowing a large number of doses to be synthesized from a comparatively small amount of raw material. Twenty five kilograms of precursor ergotamine tartrate can produce 5–6 kg of pure crystalline LSD; this corresponds to around 50–60 million doses at 100 μg. Because the masses involved are so small, concealing and transporting illicit LSD is much easier than smuggling cocaine, cannabis, or other illegal drugs.[165]

Manufacturing LSD requires laboratory equipment and experience in the field of organic chemistry. It takes two to three days to produce 30 to 100 grams of pure compound. It is believed that LSD is not usually produced in large quantities, but rather in a series of small batches. This technique minimizes the loss of precursor chemicals in case a step does not work as expected.[165]

Forms

LSD is produced in crystalline form and is then mixed with excipients or redissolved for production in ingestible forms. Liquid solution is either distributed in small vials or, more commonly, sprayed onto or soaked into a distribution medium. Historically, LSD solutions were first sold on sugar cubes, but practical considerations forced a change to tablet form. Appearing in 1968 as an orange tablet measuring about 6 mm across, "Orange Sunshine" acid was the first largely available form of LSD after its possession was made illegal. Tim Scully, a prominent chemist, made some of these tablets, but said that most "Sunshine" in the USA came by way of Ronald Stark, who imported approximately thirty-five million doses from Europe.[166]

Over a period of time, tablet dimensions, weight, shape and concentration of LSD evolved from large (4.5–8.1 mm diameter), heavyweight (≥150 mg), round, high concentration (90–350 μg/tab) dosage units to small (2.0–3.5 mm diameter) lightweight (as low as 4.7 mg/tab), variously shaped, lower concentration (12–85 μg/tab, average range 30–40 μg/tab) dosage units. LSD tablet shapes have included cylinders, cones, stars, spacecraft, and heart shapes. The smallest tablets became known as "Microdots."[167]

After tablets came "computer acid" or "blotter paper LSD," typically made by dipping a preprinted sheet of blotting paper into an LSD/water/alcohol solution.[166] [167] More than 200 types of LSD tablets have been encountered since 1969 and more than 350 blotter paper designs have been observed since 1975.[167] About the same time as blotter paper LSD came "Windowpane" (AKA "Clearlight"), which contained LSD inside a thin gelatin square a quarter of an inch (6 mm) across.[166] LSD has been sold under a wide variety of often short-lived and regionally restricted street names including Acid, Trips, Uncle Sid, Blotter, Lucy, Alice and doses, as well as names that reflect the designs on the sheets of blotter paper.[45] [168] Authorities have encountered the drug in other forms—including powder or crystal, and capsule.[169]

Modern distribution

LSD manufacturers and traffickers in the United States can be categorized into two groups: A few large-scale producers, and an equally limited number of small, clandestine chemists, consisting of independent producers who, operating on a comparatively limited scale, can be found throughout the country.[170] [171]

As a group, independent producers are of less concern to the Drug Enforcement Administration than the large-scale groups because their product reaches only local markets.[130]

Many LSD dealers and chemists describe a religious or humanitarian purpose that motivates their illicit activity. Nicholas Schou's book Orange Sunshine: The Brotherhood of Eternal Love and Its Quest to Spread Peace, Love, and Acid to the World describes one such group, the Brotherhood of Eternal Love. The group was a major American LSD trafficking group in the late 1960s and early 1970s.[172]

In the second half of the 20th century, dealers and chemists loosely associated with the Grateful Dead like Owsley Stanley, Nicholas Sand, Karen Horning, Sarah Maltzer, "Dealer McDope," and Leonard Pickard played an essential role in distributing LSD.[173]

Mimics

Since 2005, law enforcement in the United States and elsewhere has seized several chemicals and combinations of chemicals in blotter paper which were sold as LSD mimics, including DOB,[174] [175] a mixture of DOC and DOI,[176] 25I-NBOMe,[177] and a mixture of DOC and DOB.[178] Many mimics are toxic in comparatively small doses, or have extremely different safety profiles. Many street users of LSD are often under the impression that blotter paper which is actively hallucinogenic can only be LSD because that is the only chemical with low enough doses to fit on a small square of blotter paper. While it is true that LSD requires lower doses than most other hallucinogens, blotter paper is capable of absorbing a much larger amount of material. The DEA performed a chromatographic analysis of blotter paper containing 2C-C which showed that the paper contained a much greater concentration of the active chemical than typical LSD doses, although the exact quantity was not determined.[179] Blotter LSD mimics can have relatively small dose squares; a sample of blotter paper containing DOC seized by Concord, California police had dose markings approximately 6 mm apart.[180] Several deaths have been attributed to 25I-NBOMe.[181] [182] [183] [184]

Research

In the United States the earliest research began in the 1950s. Albert Kurland and his colleagues published research on LSD's therapeutic potential to treat schizophrenia. In Canada, Humphry Osmond and Abram Hoffer completed LSD studies as early as 1952.[185] By the 1960s, controversies surrounding "hippie" counterculture began to deplete institutional support for continued studies.

Currently, a number of organizations—including the Beckley Foundation, MAPS, Heffter Research Institute and the Albert Hofmann Foundation—exist to fund, encourage and coordinate research into the medicinal and spiritual uses of LSD and related psychedelics.[186] New clinical LSD experiments in humans started in 2009 for the first time in 35 years.[187] As it is illegal in many areas of the world, potential medical uses are difficult to study.[38]

In 2001 the United States Drug Enforcement Administration stated that LSD "produces no aphrodisiac effects, does not increase creativity, has no lasting positive effect in treating alcoholics or criminals, does not produce a "model psychosis", and does not generate immediate personality change."[130] More recently, experimental uses of LSD have included the treatment of alcoholism,[188] pain and cluster headache relief,[16] [189] [190] and prospective studies on depression.[191]

A 2020 meta-review indicated possible positive effects of LSD in reducing psychiatric symptoms, mainly in cases of alcoholism.[192] There is evidence that psychedelics induce molecular and cellular adaptations related to neuroplasticity and that these could potentially underlie therapeutic benefits.[193] [194]

Psychedelic therapy

See also: Psychedelic therapy. In the 1950s and 1960s, LSD was used in psychiatry to enhance psychotherapy, known as psychedelic therapy. Some psychiatrists, such as Ronald A. Sandison, who pioneered its use at Powick Hospital in England, believed LSD was especially useful at helping patients to "unblock" repressed subconscious material through other psychotherapeutic methods,[195] and also for treating alcoholism.[196] [197] One study concluded, "The root of the therapeutic value of the LSD experience is its potential for producing self-acceptance and self-surrender,"[29] presumably by forcing the user to face issues and problems in that individual's psyche.

Two recent reviews concluded that conclusions drawn from most of these early trials are unreliable due to serious methodological flaws. These include the absence of adequate control groups, lack of followup, and vague criteria for therapeutic outcome. In many cases studies failed to convincingly demonstrate whether the drug or the therapeutic interaction was responsible for any beneficial effects.[198] [199]

In recent years, organizations like the Multidisciplinary Association for Psychedelic Studies have renewed clinical research of LSD.[187]

It has been proposed that LSD be studied for use in the therapeutic setting, particularly in anxiety.[40] [41] [200] [201] In 2024, the FDA designated a form of LSD as a breakthrough therapy to treat generalized anxiety disorder.[202]

Other uses

In the 1950s and 1960s, some psychiatrists (e.g. Oscar Janiger) explored the potential effect of LSD on creativity. Experimental studies attempted to measure the effect of LSD on creative activity and aesthetic appreciation.[46] [203] [204] [205] In 1966 Dr. James Fadiman conducted a study with the central question "How can psychedelics be used to facilitate problem solving?" This study attempted to solve 44 different problems and had 40 satisfactory solutions when the FDA banned all research into psychedelics. LSD was a key component of this study.[206] [207]

Since 2008 there has been ongoing research into using LSD to alleviate anxiety for terminally ill cancer patients coping with their impending deaths.[187] [208]

A 2012 meta-analysis found evidence that a single dose of LSD in conjunction with various alcoholism treatment programs was associated with a decrease in alcohol abuse, lasting for several months, but no effect was seen at one year. Adverse events included seizure, moderate confusion and agitation, nausea, vomiting, and acting in a bizarre fashion.[30]

LSD has been used as a treatment for cluster headaches with positive results in some small studies.[16]

Recently, researchers discovered that LSD is a potent psychoplastogen, a compound capable of promoting rapid and sustained neural plasticity that may have wide-ranging therapeutic benefit.[209] LSD has been shown to increase markers of neuroplasticity in human brain organoids and improve memory performance in human subjects.[210]

LSD may have analgesic properties related to pain in terminally ill patients and phantom pain and may be useful for treating inflammatory diseases including rheumatoid arthritis.[211]

Notable individuals

Some notable individuals have commented publicly on their experiences with LSD.[212] [213] Some of these comments date from the era when it was legally available in the US and Europe for non-medical uses, and others pertain to psychiatric treatment in the 1950s and 1960s. Still others describe experiences with illegal LSD, obtained for philosophic, artistic, therapeutic, spiritual, or recreational purposes.

See also

Further reading

External links

Documentaries

Notes and References

  1. Book: Halpern JH, Suzuki J, Huertas PE, Passie T . Price LH, Stolerman IP . Encyclopedia of Psychopharmacology A Springer Live Reference. June 7, 2014. Springer-Verlag Berlin Heidelberg. Heidelberg, Germany. 978-3-642-27772-6. 1–5. Hallucinogen abuse and dependence are known complications resulting from ... LSD and psilocybin. Users do not experience withdrawal symptoms, but the general criteria for substance abuse and dependence otherwise apply. Dependence is estimated in approximately 2 % of recent-onset users . 10.1007/978-3-642-27772-6_43-2. Hallucinogen Abuse and Dependence.
  2. Encyclopedia: Definition of "amide" . Collins English Dictionary . January 31, 2015 . live . https://web.archive.org/web/20150402115318/http://www.collinsdictionary.com/dictionary/english/amide . April 2, 2015.
  3. Web site: American Heritage Dictionary Entry: amide . Ahdictionary.com . January 31, 2015 . https://web.archive.org/web/20150402134025/https://www.ahdictionary.com/word/search.html?q=amide . April 2, 2015.
  4. Web site: amide – definition of amide in English from the Oxford Dictionary. Oxforddictionaries.com . January 31, 2015 . https://web.archive.org/web/20150402184403/http://www.oxforddictionaries.com/us/definition/english/amide . April 2, 2015.
  5. Book: Neinstein LS. Adolescent Health Care: A Practical Guide . 2008. Lippincott Williams & Wilkins. 9780781792561. 931. en. January 27, 2017. December 26, 2018. https://web.archive.org/web/20181226025533/https://books.google.com/books?id=er8dQPxgcz0C&pg=PA931. live.
  6. Book: Kranzler HR, Ciraulo DA. Clinical Manual of Addiction Psychopharmacology. American Psychiatric Pub. 9781585626632. 216. en. 2 April 2007. January 27, 2017. December 26, 2018. https://web.archive.org/web/20181226025532/https://books.google.com/books?id=TYddW0uzIRsC&pg=PA216. live.
  7. Web site: Lysergide. pubchem.ncbi.nlm.nih.gov. en. April 12, 2023. April 12, 2023. https://web.archive.org/web/20230412075752/https://pubchem.ncbi.nlm.nih.gov/compound/5761#section=Solubility. live.
  8. Nichols DE . Psychedelics . Pharmacological Reviews . 68 . 2 . 264–355 . April 2016 . 26841800 . 4813425 . 10.1124/pr.115.011478 . Barker EL . 0031-6997.
  9. Web site: What are hallucinogens? . January 2016 . National Institute of Drug Abuse . April 24, 2016 . live . https://web.archive.org/web/20160417180046/https://www.drugabuse.gov/publications/drugfacts/hallucinogens . April 17, 2016.
  10. Leptourgos P, Fortier-Davy M, Carhart-Harris R, Corlett PR, Dupuis D, Halberstadt AL, Kometer M, Kozakova E, LarØi F, Noorani TN, Preller KH, Waters F, Zaytseva Y, Jardri R . Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison . Schizophrenia Bulletin . 46 . 6 . 1396–1408 . December 2020 . 32944778 . 7707069 . 10.1093/schbul/sbaa117 . Thalamocortical connectivity was found altered in psychedelic states. Specifically, LSD was found to selectively increase effective connectivity from the thalamus to certain DMN areas, while other connections are attenuated. Furthermore, increased thalamic connectivity with the right fusiform gyrus and the anterior insula correlated with visual and auditory hallucinations (AH), respectively. .
  11. Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, Duthaler U, Varghese N, Eckert A, Borgwardt S, Liechti ME . Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects . Neuropsychopharmacology . 46 . 3 . 537–544 . February 2021 . 33059356 . 8027607 . 10.1038/s41386-020-00883-6.
  12. News: Sloat S . 27 January 2017 . This is Why You Can't Escape an Hours-Long Acid Trip . Inverse . live . 3 February 2020 . June 11, 2021 . https://web.archive.org/web/20210611212737/https://www.inverse.com/article/27067-lsd-acid-trip-brain-receptor-serotonin .
  13. Liechti ME, Dolder PC, Schmid Y . Alterations of consciousness and mystical-type experiences after acute LSD in humans . Psychopharmacology . 234 . 9–10 . 1499–1510 . May 2017 . 27714429 . 5420386 . 10.1007/s00213-016-4453-0.
  14. Web site: LSD profile (chemistry, effects, other names, synthesis, mode of use, pharmacology, medical use, control status) . EMCDDA . 14 July 2018 . en . April 28, 2021 . https://web.archive.org/web/20210428113546/https://www.emcdda.europa.eu/publications/drug-profiles/lsd . live .
  15. News: Gershon L . 19 July 2016 . How LSD Went From Research to Religion . 14 July 2018 . JSTOR Daily . January 28, 2021 . https://web.archive.org/web/20210128015545/https://daily.jstor.org/how-lsd-went-from-research-to-religion/ . live .
  16. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A . The pharmacology of lysergic acid diethylamide: a review . CNS Neuroscience & Therapeutics . 14 . 4 . 295–314 . 2008 . 19040555 . 6494066 . 10.1111/j.1755-5949.2008.00059.x.
  17. Book: Halpern JH, Lerner AG, Passie T . A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. . Current Topics in Behavioral Neurosciences . 2018 . 36 . 333–360 . 978-3-662-55878-2 . 10.1007/7854_2016_457 . 27822679.
  18. Wong S, Yu AY, Fabiano N, Finkelstein O, Pasricha A, ((Jones BDM)), Rosenblat JD, Blumberger DW, Mulsant BH, Husain MI . Journal of Psychoactive Drugs . Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders . 37615379 . 10.1080/02791072.2023.2251133 . August 2023. 1–17 . 261098164.
  19. Walker SR, Pullella GA, Piggott MJ, Duggan PJ . Australian Journal of Chemistry . Introduction to the chemistry and pharmacology of psychedelic drugs . 10.1071/CH23050 . July 2023. 76 . 5 . 236–257 . free.
  20. Mallaroni P, Mason NL, ((Vinckenbosch FRJ)), Ramaekers JG . Psychopharmacology . 239 . 1783–1796 . The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides . 10.1007/s00213-022-06142-4 . April 2022. 6 . 35487983 . 9166850 . free.
  21. Nichols DE . Hallucinogens . Pharmacology & Therapeutics . 101 . 2 . 131–181 . February 2004 . 14761703 . 10.1016/j.pharmthera.2003.11.002 . 1879-016X.
  22. Girn M, Roseman L, Bernhardt B, Smallwood J, Carhart-Harris R, Spreng RN . 2020-05-03. Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex . bioRxiv . 233346402 . 10.1101/2020.05.01.072314 . free.
  23. Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ . Neural correlates of the LSD experience revealed by multimodal neuroimaging . . 113 . 17 . 4853–4858 . 11 April 2016 . 27071089 . 4855588 . 10.1073/pnas.1518377113 . 2016PNAS..113.4853C . free.
  24. Web site: Commonly Abused Drugs Charts . National Institute on Drug Abuse . 14 July 2018 . 2 July 2018 . live . https://web.archive.org/web/20200301183029/https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts#lsd . March 1, 2020.
  25. Book: Hofmann A . LSD, my problem child: reflections on sacred drugs, mysticism, and science . Santa Cruz, CA . Multidisciplinary Association for Psychedelic Studies . 2009 . 978-0-9798622-2-9 . 4th . 610059315.
  26. Book: Lee MA, Shlain B . Acid dreams: the complete social history of LSD: the CIA, the Sixties, and beyond . 1992 . Grove Weidenfeld . 0-8021-3062-3 . New York . 25281992.
  27. Book: Ettinger RH . Psychopharmacology . 2017 . Psychology Press . 978-1-351-97870-5 . 226 . en . September 27, 2021 . live . https://web.archive.org/web/20210927002241/https://books.google.com/books?id=XT4lDwAAQBAJ&pg=PA226 . September 27, 2021.
  28. Web site: Psychiatric Research with Hallucinogens . www.druglibrary.org . 2021-07-26. July 26, 2021. https://web.archive.org/web/20210726203733/https://www.druglibrary.org/schaffer/lsd/grob.htm . live.
  29. Chwelos N, Blewett DB, Smith CM, Hoffer A . Use of d-lysergic acid diethylamide in the treatment of alcoholism . Quarterly Journal of Studies on Alcohol . 20 . 3 . 577–590 . September 1959 . 13810249 . 10.15288/qjsa.1959.20.577.
  30. Krebs TS, Johansen PØ . Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials . Journal of Psychopharmacology . 26 . 7 . 994–1002 . July 2012 . 22406913 . 10.1177/0269881112439253 . 10677273.
  31. Book: United States Congress House Committee on Interstate and Foreign Commerce Subcommittee on Public Health and Welfare . Increased Controls Over Hallucinogens and Other Dangerous Drugs . 1968 . U.S. Government Printing Office . August 3, 2021. July 13, 2020 . https://web.archive.org/web/20200713014802/https://books.google.com/books?id=qbY6xQEACAAJ. live.
  32. Web site: National Institute on Drug Abuse. Hallucinogens . 14 July 2018. June 3, 2020. https://web.archive.org/web/20200603125635/https://www.drugabuse.gov/drugs-abuse/hallucinogens. live.
  33. Yockey RA, Vidourek RA, King KA . Trends in LSD use among US adults: 2015–2018 . Drug and Alcohol Dependence . 212 . 108071 . July 2020 . 32450479 . 10.1016/j.drugalcdep.2020.108071 . 218893155.
  34. Web site: DrugFacts: Hallucinogens – LSD, Peyote, Psilocybin, and PCP . National Institute on Drug Abuse . February 17, 2015. December 2014. https://web.archive.org/web/20150216030833/http://www.drugabuse.gov/publications/drugfacts/hallucinogens-lsd-peyote-psilocybin-pcp . February 16, 2015.
  35. Book: Alcohol and Drugs in North America: A Historical Encyclopedia . Fahey D, Miller JS . 978-1-59884-478-8 . 375 .
  36. San Francisco Chronicle September 20, 1966 Page One
  37. Book: Grof S, Grof JH. Stanislav Grof. Realms of the Human Unconscious (Observations from LSD Research). Souvenir Press (E & A) Ltd. 1979. London. 13–14. 978-0-285-64882-1. https://web.archive.org/web/20071018164416/http://csp.org/chrestomathy/realms_of3.html. October 18, 2007. November 18, 2007.
  38. Nutt DJ, King LA, Nichols DE . Effects of Schedule I drug laws on neuroscience research and treatment innovation . Nature Reviews. Neuroscience . 14 . 8 . 577–585 . August 2013 . 23756634 . 10.1038/nrn3530 . 1956833.
  39. News: Scientists study possible health benefits of LSD and ecstasy Science . 2016-07-23 . 2016-07-23 . live . https://web.archive.org/web/20160723155424/https://www.theguardian.com/science/2009/oct/23/lsd-ecstacy-health-benefits . July 23, 2016 . The Guardian . Campbell D.
  40. Web site: Lustberg D . 2022-10-14 . Acid for Anxiety: Fast and Lasting Anxiolytic Effects of LSD . 2022-12-01 . Psychedelic Science Review . en-US . December 1, 2022 . https://web.archive.org/web/20221201092629/https://psychedelicreview.com/acid-for-anxiety-fast-and-lasting-anxiolytic-effects-of-lsd/ . live .
  41. Holze F, Gasser P, Müller F, Dolder PC, Liechti ME . Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study . Biological Psychiatry . September 2022 . 93 . 3 . 215–223 . 10.1016/j.biopsych.2022.08.025 . 36266118 . 252095586 . free.
  42. Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE . Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years . Therapeutic Advances in Psychopharmacology . 6 . 3 . 193–213 . June 2016 . 27354908 . 4910400 . 10.1177/2045125316638008.
  43. Web site: History of LSD Therapy . 2022-11-07 . druglibrary.org . November 7, 2022 . https://web.archive.org/web/20221107004840/https://druglibrary.org/schaffer/lsd/grofhist.htm . live .
  44. Majić T, Schmidt TT, Gallinat J . Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? . Journal of Psychopharmacology . 29 . 3 . 241–253 . March 2015 . 25670401 . 10.1177/0269881114568040 . 16483172.
  45. Web site: . Honig D . Frequently Asked Questions . https://web.archive.org/web/20160212232436/https://www.erowid.org/chemicals/lsd/lsd_faq.shtml . 12 February 2016.
  46. McGlothlin W, Cohen S, McGlothlin MS . Long lasting effects of LSD on normals . Archives of General Psychiatry . 17 . 5 . 521–532 . November 1967 . 6054248 . 10.1001/archpsyc.1967.01730290009002. April 30, 2011 . https://web.archive.org/web/20110430020912/http://www.maps.org/w3pb/new/1967/1967_mcglothlin_4655_1.pdf.
  47. Katz MM, Waskow IE, Olsson J . Characterizing the psychological state produced by LSD . Journal of Abnormal Psychology . 73 . 1 . 1–14 . February 1968 . 5639999 . 10.1037/h0020114 . 10.1.1.409.4030.
  48. Archives of General Psychiatry . Subjective Reactions to Lysergic Acid Diethylamide (LSD-25) . May 1962 . 6 . 5 . 352–368 . 10.1001/archpsyc.1962.01710230020003 . Linton HR, Langs RJ.
  49. Parker LA . LSD produces place preference and flavor avoidance but does not produce flavor aversion in rats . Behavioral Neuroscience . 110 . 3 . 503–508 . June 1996 . 8888996 . 10.1037/0735-7044.110.3.503.
  50. Oster G . Moiré patterns and visual hallucinations . Psychedelic Review . 1966 . 7 . 33–40 . live . 19 April 2017 . https://web.archive.org/web/20170419154504/http://www.maps.org/research-archive/psychedelicreview/n07/n07033osl.pdf.
  51. Kaelen M, Roseman L, Kahan J, Santos-Ribeiro A, Orban C, Lorenz R, Barrett FS, Bolstridge M, Williams T, Williams L, Wall MB, Feilding A, Muthukumaraswamy S, Nutt DJ, Carhart-Harris R . July 2016 . LSD modulates music-induced imagery via changes in parahippocampal connectivity . European Neuropsychopharmacology . 26 . 7 . 1099–1109 . 27084302 . 10.1016/j.euroneuro.2016.03.018 . 24037275.
  52. Forensic Science International . Nichols DE, Grob CS . 10.1016/j.forsciint.2018.01.006 . Is LSD Toxic? . 284 . 141–145 . March 2018 . 29408722.
  53. Nutt DJ, King LA, Phillips LD . Drug harms in the UK: a multicriteria decision analysis . Lancet . 376 . 9752 . 1558–65 . November 2010 . 21036393 . 10.1016/s0140-6736(10)61462-6 . 5667719 . 10.1.1.690.1283.
  54. Krebs TS, Johansen PØ . Psychedelics and mental health: a population study . PLOS ONE . 8 . 8 . e63972 . 2013-08-19 . 23976938 . 3747247 . 10.1371/journal.pone.0063972 . 2013PLoSO...863972K . Lu L . free.
  55. Web site: Is Military Research Hazardous to Veterans Health? Lessons Spanning Half A Century, part F. HALLUCINOGENS . 103rd Congress, 2nd Session-S. Prt. 103-97; Staff Report prepared for the committee on veterans' affairs . December 8, 1994 . Rockefeller IV JD . West Virginia . https://web.archive.org/web/20060813164326/http://gulfweb.org/bigdoc/rockrep.cfm#hallucinogens . August 13, 2006 . December 13, 2018.
  56. Middlefell R . The effects of LSD on body sway suggestibility in a group of hospital patients . The British Journal of Psychiatry . 113 . 496 . 277–280 . March 1967 . 6029626 . 10.1192/bjp.113.496.277 . 19439549 . https://web.archive.org/web/20110430033215/http://www.lycaeum.org/research/researchpdfs/1489.pdf . 2011-04-30.
  57. Sjoberg BM, Hollister LE . The effects of psychotomimetic drugs on primary suggestibility . Psychopharmacologia . 8 . 4 . 251–262 . November 1965 . 5885648 . 10.1007/BF00407857 . 15249061.
  58. Halpern JH, Pope HG . Hallucinogen persisting perception disorder: what do we know after 50 years? . Drug and Alcohol Dependence . 69 . 2 . 109–19 . March 2003 . 12609692 . 10.1016/S0376-8716(02)00306-X.
  59. Müller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S . Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants . Psychopharmacology . January 2022 . 239 . 6 . 1933–1943 . 35076721 . 10.1007/s00213-022-06066-z . 9166883 . 246276633.
  60. Johansen PØ, Krebs TS . Psychedelics not linked to mental health problems or suicidal behavior: a population study . Journal of Psychopharmacology . 29 . 3 . 270–279 . March 2015 . 10.1177/0269881114568039 . 25744618 . 2025731.
  61. Book: Holland D, Passie T . 978-3-86135-207-5 . de . 2011 . Flashback-Phänomene als Nachwirkung von Halluzinogeneinnahme . 2 . Bewusstsein – Kognition – Erleben . VWB Report . June 9, 2023 . June 9, 2023 . https://web.archive.org/web/20230609015208/http://www.vwb-verlag.com/Katalog/m207.html . live .
  62. Abraham HD, Duffy FH . October 1996 . Stable quantitative EEG difference in post-LSD visual disorder by split-half analysis: evidence for disinhibition . Psychiatry Research . 67 . 3 . 173–87 . 8912957 . 10.1016/0925-4927(96)02833-8 . 7587687.
  63. Book: Psychedelics as Psychiatric Medications . . 9780192678522 . 7 March 2023 . Nutt DJ, Castle D . Drug-interaction with psychotropic drugs . May 21, 2023 . May 21, 2023 . https://web.archive.org/web/20230521000115/https://books.google.com/books?id=7lazEAAAQBAJ . live .
  64. Drug and Alcohol Dependence . 239 . 109586 . Simonsson O, Goldberg SB, Chambers R, Osika W, Long DM, Hendricks PS . 1 October 2022 . 35981469 . 9627432 . Prevalence and associations of classic psychedelic-related seizures in a population-based sample . 10.1016/j.drugalcdep.2022.109586.
  65. 1967 . Western Journal of Medicine . Fisher D, Ungerleider J . 4962683 . 1502729 . 106 . 3 . 201–211 . Grand mal seizures following ingestion of LSD.
  66. Book: Buchborn T, Grecksch G, Dieterich D, Hollt V . Neuropathology of Drug Addictions and Substance Misuse . 10.1016/B978-0-12-800212-4.00079-0 . Chapter 79 - Tolerance to Lysergic Acid Diethylamide: Overview, Correlates, and Clinical Implications . 978-0-12-800212-4 . . 848–849 . 2 . 2016.
  67. A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects . Dolder DS, Grünblatt E, Müller F, Borgwardt SJ, Liechti ME . 28 June 2017 . 10.3389/fphar.2017.00423 . Frontiers in Neuroscience . 8 . 423 . 28701958 . 5487530 . free.
  68. Pain Practice . 455 . 23 . 4 . 1533-2500 . 10.1111/papr.13203 . free . Kooijman NI, Willegers T, Reuser A, Mulleners WM, Kramers C, ((Vissers KCP)), ((van der Wal SEI)) . 4 January 2023 . 36597700 . Are psychedelics the answer to chronic pain: A review of current literature. 255470638 . 2066/291903 . free.
  69. Wolbach AB, Isbell H, Miner EJ . March 1962 . Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions . Psychopharmacologia . 3 . 1–14 . 14007904 . 10.1007/BF00413101 . 23803624 . December 1, 2007 . April 19, 2014 . https://web.archive.org/web/20140419141528/http://www.erowid.org/references/refs_view.php?A=ShowDocPartFrame&C=ref&ID=2032&DocPartID=1893.
  70. Isbell H, Wolbach AB, Wikler A, Miner EJ . Cross tolerance between LSD and psilocybin . Psychopharmacologia . 2 . 3 . 147–159 . 1961 . 10.1007/BF00407974 . December 1, 2007 . 13717955 . 7746880 . March 15, 2016 . https://web.archive.org/web/20160315102433/https://www.erowid.org/references/refs_view.php?a=showdocpartframe&c=ref&docpartid=1843&id=1979 . live .
  71. Jonas S, Downer JD . Gross behavioural changes in monkeys following administration of LSD-25, and development of tolerance to LSD-25 . Psychopharmacologia . 6 . 4 . 303–386 . October 1964 . 4953438 . 10.1007/BF00413161 . 11768927.
  72. Schlemmer RF, Nawara C, Heinze WJ, Davis JM, Advokat C . Influence of environmental context on tolerance to LSD-induced behavior in primates . Biological Psychiatry . 21 . 3 . 314–317 . March 1986 . 3947713 . 10.1016/0006-3223(86)90053-3 . 35508993.
  73. Lüscher C, Ungless MA . The mechanistic classification of addictive drugs . PLOS Medicine . 3 . 11 . e437 . November 2006 . 17105338 . 1635740 . 10.1371/journal.pmed.0030437 . free.
  74. Book: Malenka RC, Nestler EJ, Hyman SE . Sydor A, Brown RY . Molecular Neuropharmacology: A Foundation for Clinical Neuroscience . 2009 . McGraw-Hill Medical . New York . 9780071481274 . 375 . 2nd . Chapter 15: Reinforcement and Addictive Disorders . Several other classes of drugs are categorized as drugs of abuse but rarely produce compulsive use. These include psychedelic agents, such as lysergic acid diethylamide (LSD) . June 12, 2023 . August 28, 2023 . https://web.archive.org/web/20230828020503/https://books.google.com/books?id=PjgfBQAAQBAJ . live .
  75. Balestrieri A, Fontanari D . September 1959 . 10.1001/archpsyc.1959.03590030063008 . 279–282 . 13796178 . Acquired and crossed tolerance to mescaline, LSD-25, and BOL-148. Archives of General Psychiatry . 1 . 3.
  76. Current Neuropharmacology . 17 . 2 . 1–15 . Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness . 10.2174/1570159X16666180125095902 . free . 1875-6190 . Hamill J, Hallak J, Dursun SD, Baker G . 2019 . 29366418. 6343205.
  77. Addiction . Society for the Study of Addiction . Morgenstern J, Langenbucher J, Labouvie E . September 1994 . The generalizability of the dependence syndrome across substances: an examination of some properties of the proposed DSM-IV dependence criteria . 89 . 9 . 1105–1113 . 10.1111/j.1360-0443.1994.tb02787.x . 7987187.
  78. Li JH, Lin LF . Genetic toxicology of abused drugs: a brief review . Mutagenesis . 13 . 6 . 557–65 . November 1998 . 9862186 . 10.1093/mutage/13.6.557 . free.
  79. Transformative Medicine . NBOMe Toxicity and Fatalities: A Review of the Literature . 1 . 1 . March 2022 . Lipow M, Kaleem SZ, Espiridion E . 12–18 . 247888583 . 10.54299/tmed/msot8578 . free . 2831-8978.
  80. Klock JC, Boerner U, Becker CE . Coma, Hyperthermia and Bleeding Associated with Massive LSD Overdose: A Report of Eight Cases . The Western Journal of Medicine . March 1974 . 120 . 3 . 183–188 . 4816396 . 1129381.
  81. Frontiers in Neuroscience . Zawilska JB, Kacela M, Adamowicz P . 10.3389/fnins.2020.00078 . 26 February 2020 . 14 . 32174803 . NBOMes–Highly Potent and Toxic Alternatives of LSD . 78 . 7054380 . free.
  82. Hartogsohn I . 2017 . Constructing drug effects: A history of set and setting . Drug Science, Policy and Law . en . 3 . 205032451668332 . 10.1177/2050324516683325 . 53373205 . 2050-3245 . free.
  83. Biochemical Pharmacology . Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A . Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors . 10.1016/j.bcp.2018.09.024 . 30261175 . 6298744 . 158 . 27–34 . December 2018.
  84. Journal of Analytical Toxicology . 10.1093/jat/bkv073 . 4570937 . 26378135 . Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper . Poklis JL, Raso SA, Alford KN, Poklis A, Peace MR . Oct 2015 . 39 . 8 . 617–623.
  85. . A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD) . Ivory ST, Rotella J, Schumann J, Greene SL . 966–969 . 28 March 2022 . 60 . 8 . 10.1080/15563650.2022.2053150 . 35343858 . 247764056.
  86. Frontiers in Pharmacology . 12 December 2019 . Miliano C, Marti M, Pintori N, Castelli MP, Tirri M, Arfè R, De Luca MA . Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe . 10 . 1406 . 31915427 . 6921684 . 10.3389/fphar.2019.01406 . free.
  87. Book: Neuropharmacology of New Psychoactive Substances . Halberstadt AL . 10.1007/7854_2016_64 . 18 January 2017 . 978-3-319-52444-3 . Springer . Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens . Current Topics in Behavioral Neurosciences . 32 . 283–311 . 28097528.
  88. Duffau B, Camargo C, Kogan M, Fuentes E, Kennedy Cassels B . Journal of Chromatographic Science . 54 . 7 . August 2016 . 1153–1158 . Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC–MS . 4941995 . 27406128 . 10.1093/chromsci/bmw095 . free.
  89. 25105138 . 4106087 . 10.1155/2014/734749 . 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug . BioMed Research International . 3 July 2014 . Francesco SB, Ornella C, Gabriella A, Giuseppe V, Rita S, Flaminia BP, Eduardo C, Pierluigi S, Giovanni M, Guiseppe B, Fabrizio S . 2014 . 734749 . free.
  90. Book: Novel Psychoactive Substances: Classification, Pharmacology and Toxicology . Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens . Potts AJ, ((Thomas SHL)), Hill SL . Dargan P, Wood D . 10.1016/B978-0-12-818788-3.00008-5 . 978-0-12-818788-3 . 279–300 . 2nd . Academic Press . September 2021 . 240583877.
  91. Marona-Lewicka D, Thisted RA, Nichols DE . Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis . Psychopharmacology . 180 . 3 . 427–35 . July 2005 . 15723230 . 10.1007/s00213-005-2183-9 . 23565306 .
  92. Nelson DL . 5-HT5 receptors . Current Drug Targets. CNS and Neurological Disorders . 3 . 1 . 53–58 . February 2004 . 14965244 . 10.2174/1568007043482606.
  93. Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J . Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists . Neuroscience Letters . 493 . 3 . 76–79 . April 2011 . 21276828 . 3064746 . 10.1016/j.neulet.2011.01.046.
  94. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB . Functional selectivity and classical concepts of quantitative pharmacology . The Journal of Pharmacology and Experimental Therapeutics . 320 . 1 . 1–13 . January 2007 . 16803859 . 10.1124/jpet.106.104463 . 447937 . June 11, 2023 . June 11, 2023 . https://web.archive.org/web/20230611010342/https://jpet.aspetjournals.org/content/320/1/1 . live .
  95. Aghajanian GK, Marek GJ . Serotonin and hallucinogens . Neuropsychopharmacology . 21 . 2 Suppl . 16S–23S . August 1999 . 10432484 . 10.1016/S0893-133X(98)00135-3 . free .
  96. Svenningsson P, Nairn AC, Greengard P . DARPP-32 mediates the actions of multiple drugs of abuse . The AAPS Journal . 7 . 2 . E353-60 . October 2005 . 16353915 . 2750972 . 10.1208/aapsj070235 .
  97. Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K . Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes . Biochemical and Biophysical Research Communications . 443 . 1 . 278–84 . January 2014 . 24309097 . 10.1016/j.bbrc.2013.11.104 .
  98. Green JP, Johnson CL, Weinstein H, Maayani S . Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide . Proceedings of the National Academy of Sciences of the United States of America . 74 . 12 . 5697–701 . December 1977 . 23536 . 431860 . 10.1073/pnas.74.12.5697 . 1977PNAS...74.5697G . free .
  99. Chen Q, Tesmer JJ . A Receptor on Acid . Cell . 168 . 3 . 339–341 . January 2017 . 10.1016/j.cell.2017.01.012 . 28129534 . 5520807.
  100. Wacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, Lansu K, Schools ZL, Che T, Nichols DE, Shoichet BK, Dror RO, Roth BL . Crystal Structure of an LSD-Bound Human Serotonin Receptor . Cell . 168 . 3 . 377–389.e12 . January 2017 . 28129538 . 5289311 . 10.1016/j.cell.2016.12.033 .
  101. Book: Shulgin A, Shulgin A . Alexander Shulgin . Ann Shulgin . http://www.erowid.org/library/books_online/tihkal/tihkal26.shtml . 15 October 2008 . http://archive.wikiwix.com/cache/20081015082653/http://www.erowid.org/library/books_online/tihkal/tihkal26.shtml . LSD . . Berkeley, CA . Transform Press . 1997 . 0-9630096-9-9.
  102. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A . The pharmacology of lysergic acid diethylamide: a review . CNS Neuroscience & Therapeutics . 14 . 4 . 295–314 . 2008-11-11 . 19040555 . 6494066 . 10.1111/j.1755-5949.2008.00059.x .
  103. Aghajanian GK, Bing OH . Persistence of lysergic acid diethylamide in the plasma of human subjects . Clinical Pharmacology and Therapeutics . 5 . 5 . 611–614 . 1964 . 14209776 . 10.1002/cpt196455611. 29438767 . https://web.archive.org/web/20090327144227/http://www.maps.org/w3pb/new/1964/1964_aghajanian_2224_1.pdf . March 27, 2009.
  104. Papac DI, Foltz RL . Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry . Journal of Analytical Toxicology . 14 . 3 . 189–190 . May–June 1990 . 2374410 . 10.1093/jat/14.3.189 . live. PDF . April 29, 2011. https://web.archive.org/web/20110429060433/http://www.erowid.org/references/refs_view.php?A=ShowDocPartFrame&C=ref&ID=6265&DocPartID=6624.
  105. Singleton SP, Luppi AI, Carhart-Harris RL, Cruzat J, Roseman L, Nutt DJ, Deco G, Kringelbach ML, Stamatakis EA, Kuceyeski A . Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape. Nat Commun . 13 . 1 . 5812 . Oct 2022 . 36192411 . 10.1038/s41467-022-33578-1 . 9530221 . 2022NatCo..13.5812S . free .
  106. Delli Pizzi S, Chiacchiaretta P, Sestieri C, Ferretti A, Onofrj M, Della Penna S, Roseman L, Timmermann C, Nutt DJ, Carhart-Harris RL, Sensi SL . Spatial Correspondence of LSD-Induced Variations on Brain Functioning at Rest With Serotonin Receptor Expression . Biol Psychiatry Cogn Neurosci Neuroimaging . 8 . 7 . 768–776 . July 2023 . 37003409 . 10.1016/j.bpsc.2023.03.009 . 257862535.
  107. Delli Pizzi S, Chiacchiaretta P, Sestieri C, Ferretti A, Tullo MG, Della Penna S, Martinotti G, Onofrj M, Roseman L, Timmermann C, Nutt DJ, Carhart-Harris RL, Sensi SL . LSD-induced changes in the functional connectivity of distinct thalamic nuclei . NeuroImage . 283 . 120414 . Dec 2023 . 37858906 . 10.1016/j.neuroimage.2023.120414 . free.
  108. Book: Handbook of Medical Hallucinogens . 2021 . Guilford Publications . 9781462545452 . 160 . en . LSD . https://mcb.berkeley.edu/labs2/presti/sites/mcb.berkeley.edu.labs2.presti/files/u3/2021%20LSD%20Chapter%20Panik%20Presti.pdf . March 14, 2024 . March 14, 2024 . https://web.archive.org/web/20240314163910/https://mcb.berkeley.edu/labs2/presti/sites/mcb.berkeley.edu.labs2.presti/files/u3/2021%20LSD%20Chapter%20Panik%20Presti.pdf . live .
  109. Monte AP, Marona-Lewicka D, Kanthasamy A, Sanders-Bush E, Nichols DE . March 1995 . Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes . Journal of Medicinal Chemistry . 38 . 6 . 958–66 . 7699712 . 10.1021/jm00006a015.
  110. Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM . September 2002 . Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD) . Journal of Medicinal Chemistry . 45 . 19 . 4344–9 . 12213075 . 10.1021/jm020153s.
  111. Web site: Extraction of LSA (Method #1) . Erowid . September 25, 2014 . https://web.archive.org/web/20140926235219/http://www.erowid.org/plants/morning_glory/morning_glory_extraction1.shtml . September 26, 2014 . live.
  112. Kornfeld EC, Fornefeld EJ, Kline GB, Mann MJ, Morrison DE, Jones RG, Woodward RB . The Total Synthesis of Lysergic Acid . Journal of the American Chemical Society . 78 . 13 . 3087–3114 . 1956 . 10.1021/ja01594a039.
  113. Inuki S, Oishi S, Fujii N, Ohno H . Total synthesis of (+/-)-lysergic acid, lysergol, and isolysergol by palladium-catalyzed domino cyclization of amino allenes bearing a bromoindolyl group . Organic Letters . 10 . 22 . 5239–42 . November 2008 . 18956869 . 10.1021/ol8022648 .
  114. Web site: ((National University of Singapore, Yong Loo Lin School of Medicine)) . 10 February 2022 . Harvesting baker's yeast for aging-related therapeutics . ScienceDaily . 2023-05-04 . November 27, 2022 . https://web.archive.org/web/20221127230250/https://www.sciencedaily.com/releases/2022/02/220210154135.htm . live . Journal Reference: Wong G, Lim LR, Tan YQ, Go MK, Bell DJ, Freemont PS, Yew WS . Reconstituting the complete biosynthesis of D-lysergic acid in yeast . Nature Communications . 13 . 1 . 712 . February 2022 . 10.1038/s41467-022-28386-6 . 35132076 . 8821704 . 2022NatCo..13..712W.
  115. Greiner T, Burch NR, Edelberg R . Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum . A.M.A. Archives of Neurology and Psychiatry . 79 . 2 . 208–10 . February 1958 . 13497365 . 10.1001/archneurpsyc.1958.02340020088016.
  116. Meyer MA . Neurologic complications of anthrax: a review of the literature . Archives of Neurology . 60 . 4 . 483–8 . April 2003 . 12707059 . 10.1001/archneur.60.4.483 . free . Schweiz.
  117. Polito V, Stevenson RJ . A systematic study of microdosing psychedelics . PLOS ONE . 14 . 2 . e0211023 . 2019-02-06 . 30726251 . 6364961 . 10.1371/journal.pone.0211023 . 2019PLoSO..1411023P . free.
  118. Web site: Hidalgo E. 2009. LSD Samples Analysis. Erowid. February 8, 2010. live. https://web.archive.org/web/20100213145552/http://www.erowid.org/chemicals/lsd/lsd_article3.shtml. February 13, 2010.
  119. Book: Henderson LA, Glass WJ . LSD: Still with us after all these years . 1994 . 978-0-7879-4379-0 . Jossey-Bass . San Francisco.
  120. Web site: Fire & Earth Erowid. Nov 2003. LSD Analysis – Do we know what's in street acid?. Erowid. February 8, 2010. https://web.archive.org/web/20100126215446/http://www.erowid.org/chemicals/lsd/lsd_article1.shtml. January 26, 2010. live.
  121. Li Z, McNally AJ, Wang H, Salamone SJ . Stability study of LSD under various storage conditions . Journal of Analytical Toxicology . 22 . 6 . 520–5 . October 1998 . 9788528 . 10.1093/jat/22.6.520 . free .
  122. Appel JB, Whitehead WE, Freedman DX . July 1968 . Motivation and the behavioral effects of LSD . Psychonomic Science . en . 12 . 7 . 305–306 . 10.3758/BF03331322 . 144527673 . 0033-3131. free .
  123. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 12th edition, Biomedical Publications, Foster City, CA, 2020, pp. 1197–1199.
  124. Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME . Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects . Clinical Pharmacokinetics . 56 . 10 . 1219–1230 . October 2017 . 28197931 . 10.1007/s40262-017-0513-9 . 5591798 .
  125. Jiaming Z, Xin W, Jiali Z, Hang R, Yunli Z, Ping X . Concentrations of LSD, 2-oxo-3-hydroxy-LSD, and iso-LSD in hair segments of 18 drug abusers . Forensic Science International . 344 . March 2023 . 36753839 . 10.1016/j.forsciint.2023.111578. 256574276.
  126. Hofmann A . Albert Hofmann. Ott J . LSD Ganz Persönlich . LSD: Completely Personal . Summer 1969 . MAPS . 6 . 69 . de . https://web.archive.org/web/20131206032629/http://www.maps.org/news-letters/v06n3/06346hof.html . 6 December 2013.
  127. Book: Medicinal Chemistry: A Molecular and Biochemical Approach . Nogrady T, Weaver DF . 2005 . Oxford University Press . 978-0-19-028296-7 . 342 . en . March 14, 2020 . live . https://web.archive.org/web/20210308133740/https://www.google.com/books/edition/Medicinal_Chemistry/TNXeDAAAQBAJ?hl=en&gbpv=1&dq=%22LysergS%C3%A4ureDiethylamid%22+abreviation+LSD&pg=PT342 . March 8, 2021.
  128. Web site: Hypothesis on Albert Hofmann's Famous 1943 "Bicycle Day" . September 27, 2007 . Nichols D . May 24, 2003 . Hofmann Foundation . September 22, 2007 . https://web.archive.org/web/20070922215008/http://www.erowid.org/general/conferences/conference_mindstates4_nichols.shtml . live.
  129. Web site: History Of LSD . September 27, 2007 . Hofmann A . https://web.archive.org/web/20070904212518/http://www.a1b2c3.com/drugs/lsd01.htm . September 4, 2007.
  130. Oct 1995 . LSD: The Drug . LSD in the United States . U.S. Department of Justice, Drug Enforcement Administration . http://www.usdoj.gov/dea/pubs/lsd/lsd-4.htm . November 27, 2010 . April 27, 1999 . https://web.archive.org/web/19990427145322/http://www.usdoj.gov/dea/pubs/lsd/lsd-4.htm.
  131. News: The CIA's Secret Quest For Mind Control: Torture, LSD And A 'Poisoner In Chief' . NPR.org . 6 October 2019 . en . June 28, 2021 . https://web.archive.org/web/20210628081520/https://www.npr.org/2019/09/09/758989641/the-cias-secret-quest-for-mind-control-torture-lsd-and-a-poisoner-in-chief . live .
  132. Web site: How LSD was popularized . Brecher EM . Editors of Consumer Reports Magazine . 1972 . Druglibrary.org . 20 June 2012 . live . https://web.archive.org/web/20120513233708/http://druglibrary.org/schaffer/Library/studies/cu/CU50.html . 13 May 2012.
  133. Web site: Applebaum A . Anne Applebaum . Did The Death Of Communism Take Koestler And Other Literary Figures With It? . . 26 January 2010 . http://archive.wikiwix.com/cache/20110714161713/http://www.huffingtonpost.com/2010/01/26/did-the-death-of-communis_n_435939.html . 14 July 2011.
  134. Web site: Out-Of-Sight! SMiLE Timeline . October 30, 2011. https://web.archive.org/web/20100201234435/http://pages.cthome.net/tobelman/The_Out-Of-Sight_SMiLE_Site.html . February 1, 2010.
  135. Book: Veysey LR . . Chicago IL . University of Chicago Press . 1978 . 0-226-85458-2 . 437.
  136. Web site: Staggers-Dodd Bill, Public Law 90-639 . United States Congress . October 24, 1968 . September 8, 2009 . live . https://web.archive.org/web/20100509025200/http://www.erowid.org/psychoactives/law/law_fed_staggers-dodd.pdf . May 9, 2010.
  137. Web site: Psycholytic Therapy with MDMA and LSD in Switzerland . Gasser P . 1994 . September 8, 2009 . live . October 11, 2009 . https://web.archive.org/web/20091011083518/http://www.maps.org/news-letters/v05n3/05303psy.html.
  138. Web site: Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in 'psychedelic renaissance'. Feuer W. November 4, 2020 . CNBC. November 7, 2020 . live. November 4, 2020. https://web.archive.org/web/20201104155737/https://www.cnbc.com/2020/11/04/oregon-becomes-first-state-to-legalize-magic-mushrooms-as-more-states-ease-drug-laws.html.
  139. Book: DeRogatis J . Turn On Your Mind: Four Decades of Great Psychedelic Rock . Milwaukie, Michigan . Hal Leonard . 2003 . 0-634-05548-8 . 8–9.
  140. Web site: Show 41 – The Acid Test: Psychedelics and a sub-culture emerge in San Francisco. [Part 1] : UNT Digital Library | vauthors = Gilliland J |year=1969 |author-link=John Gilliland |website=[[Pop Chronicles]] |publisher=Digital.library.unt.edu |format=audio |access-date=May 6, 2011 |url-status=live |archive-url=http://archive.wikiwix.com/cache/20110629170356/https://digital.library.unt.edu/ark:/67531/metadc19800/m1/ |archive-date=June 29, 2011].
  141. Book: Hicks M . Sixties Rock: Garage, Psychedelic, and Other Satisfactions Music in American Life . Chicago, IL . University of Illinois Press . 2000 . 0-252-06915-3 . 60 .
  142. Book: Mann J . Turn on and Tune in: Psychedelics, Narcotics and Euphoriants . Royal Society of Chemistry . 2009 . 978-1-84755-909-8 . 87 .
  143. Web site: OBITUARY — Ron Thelin . Taylor M . 1996-03-22 . SFGate . 2020-05-13 . live . August 28, 2021 . https://web.archive.org/web/20210828153344/https://www.sfgate.com/news/article/OBITUARY-Ron-Thelin-2989153.php.
  144. Davis JC . The business of getting high: head shops, countercultural capitalism, and the marijuana legalization movement. . The Sixties . January 2015 . 8 . 1 . 27–49 . 10.1080/17541328.2015.1058480 . 11603/7422 . 142795620 . free.
  145. Book: Conners . Peter . White Hand Society - The Psychedelic Partnership of Timothy Leary and Allen Ginsberg . City Lights Books . 2010 . 9780872865358 . 148 . registration .
  146. Gilmore M . Beatles' Acid Test: How LSD Opened the Door to 'Revolver' . Rolling Stone . August 25, 2016 . December 9, 2021 . December 3, 2020 . https://web.archive.org/web/20201203211257/https://www.rollingstone.com/feature/beatles-acid-test-how-lsd-opened-the-door-to-revolver-251417/ . live.
  147. Book: Rubin R, Melnick JP . Immigration and American Popular Culture: an Introduction . New York, NY . New York University Press . 2007 . 978-0-8147-7552-3 . 162–4.
  148. Book: Prown P, Newquist HP, Eiche JF . Legends of Rock Guitar: the Essential Reference of Rock's Greatest Guitarists . London . Hal Leonard Corporation, 1997 . 0-7935-4042-9 . 48 . 1997.
  149. Book: Sheff D . 2000 . David Sheff . All We Are Saying: The Last Major Interview with John Lennon and Yoko Ono . St. Martin's Press . New York . 978-0-312-25464-3 . registration.
  150. Thompson T . 16 June 1967 . The New Far-Out Beatles . Life . Chicago . Time Inc. . 101 . 8 Dec 2016 . November 17, 2021 . https://web.archive.org/web/20211117042255/https://books.google.com/books?id=lVYEAAAAMBAJ&pg=101 . live.
  151. Book: Keith Haring: Journey of the Radiant Baby . Bunker Hill Publishing . 2006 . 1593730527 . Haring K . 25 . December 5, 2023 . October 2, 2023 . https://web.archive.org/web/20231002134101/https://books.google.com/books?id=PElY27UXXkYC . live .
  152. News: Why Certain Drugs Make Specific Genres Sound So Good . Vice . Daisy Jones . 5 June 2017 . December 5, 2023 . December 5, 2023 . https://web.archive.org/web/20231205200458/https://www.vice.com/en/article/newv7g/why-drugs-genres-match-mdma-raves-shrooms-psychedelia-rap-lean . live .
  153. Web site: Phishin' With Matisyahu: How LSD "Turned My Entire World Inside Out" . Kendall Deflin . 22 June 2017 . December 5, 2023 . September 30, 2023 . https://web.archive.org/web/20230930095840/https://liveforlivemusic.com/features/phish-matisyahu-nyc/ . live .
  154. Web site: How LSD influenced Western culture . 2024-01-08 . www.bbc.com . November 27, 2020 . https://web.archive.org/web/20201127003729/https://www.bbc.com/culture/article/20181016-how-lsd-influenced-western-culture . live .
  155. Web site: UN Convention on Psychotropic Substances . 1971 . Final act of the United Nations Conference . https://web.archive.org/web/20120415011336/http://www.unodc.org/pdf/convention_1971_en.pdf . 15 April 2012.
  156. Web site: Poisons Standard . July 2016 . https://web.archive.org/web/20170302025331/https://www.legislation.gov.au/Details/F2017L00057 . 2 March 2017 . Therapeutic Goods Administration . Australian Government Department of Health.
  157. Web site: Misuse of Drugs Act 1981 . 18 November 2015 . Government of Western Australia . https://web.archive.org/web/20151222180141/http://www.slp.wa.gov.au/pco/prod/FileStore.nsf/Documents/MRDocument%3A28280P/%24FILE/Misuse%20Of%20Drugs%20Act%201981%20-%20%5B06-e0-00%5D.pdf?OpenElement . 22 December 2015.
  158. Web site: Controlled Drugs and Substances Act . December 15, 2013 . Canadian Department of Justice . 1996 . Canadian government . Justice Laws . https://web.archive.org/web/20131215170432/http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-26.html . December 15, 2013 .
  159. Web site: Drugs and the law: Report of the inquiry into the Misuse of Drugs Act 1971 . https://web.archive.org/web/20160130144204/http://www.druglibrary.org/schaffer/Library/studies/runciman/pf3.htm . 30 January 2016 . London . Police Foundation . 2000 . Runciman Report.
  160. Web site: After the War on Drugs: Blueprint for Regulation . https://web.archive.org/web/20131005145241/http://www.tdpf.org.uk/blueprint%20download.htm . 5 October 2013 . Transform Drug Policy Foundation . 2009.
  161. Neal v. United States. U.S.. 516. 284. 1996. https://www.law.cornell.edu/supct/html/94-9088.ZO.html. https://web.archive.org/web/20160409213251/https://www.law.cornell.edu/supct/html/94-9088.ZO.html. live., originating from U.S. v. Neal, 46 F.3d 1405 (7th Cir. 1995)
  162. Web site: Jaeger K. 2021-06-29. California Lawmakers Approve Bill To Legalize Psychedelics Possession In Committee. 2021-07-08. Marijuana Moment. en-US. July 9, 2021. https://web.archive.org/web/20210709172122/https://www.marijuanamoment.net/california-lawmakers-approve-bill-to-legalize-psychedelics-possession-in-committee/. live.
  163. Web site: Ley de Narcomenudeo . https://web.archive.org/web/20101130224127/http://www.elpensador.com.mx/2009/10/17/Ley-de-Narcomenudeo/ . 30 November 2010 . es . El Pensador . 17 October 2009.
  164. Parliament of the Czech Republic . 1998 . Explanatory Report to Act No. 112/1998 Coll., which amends the Act No. 140/1961 Coll., the Criminal Code, and the Act No. 200/1990 Coll., on misdemeanors . Prague . cs.
  165. Web site: DEA . 2007 . LSD Manufacture – Illegal LSD Production . LSD in the United States . U.S. Department of Justice Drug Enforcement Administration . https://web.archive.org/web/20070829023659/https://fas.org/irp/agency/doj/dea/product/lsd/lsd-5.htm. August 29, 2007.
  166. Book: Stafford P . 1992 . Psychedelics Encyclopaedia . Chapter 1 – The LSD Family . 62 . 3rd . Ronin Publishing . 978-0-914171-51-5.
  167. Book: Laing RR, Beyerstein BL, Siegel JA . 2003 . Hallucinogens: A Forensic Drug Handbook . Chapter 2.2 – Forms of the Drug . https://books.google.com/books?id=l1DrqgobbcwC . 39–41 . Academic Press . 978-0-12-433951-4 . May 12, 2020 . February 2, 2021 . https://web.archive.org/web/20210202134552/https://books.google.com/books?id=l1DrqgobbcwC . live.
  168. Web site: Street Terms: Drugs and the Drug Trade. April 5, 2005. Office of National Drug Control Policy. January 31, 2007. live. https://web.archive.org/web/20090418031446/http://www.whitehousedrugpolicy.gov/streetTerms/ByType.asp?intTypeID=6. April 18, 2009.
  169. Web site: DEA . 2008 . Photo Library (page 2) . US Drug Enforcement Administration . June 27, 2008 . https://web.archive.org/web/20080623111640/http://www.usdoj.gov/dea/photo_library2.html . June 23, 2008.
  170. Book: MacLean JR, Macdonald DC, Ogden F, Wilby E . LSD-25 and mescaline as therapeutic adjuvants. . Abramson H . The Use of LSD in Psychotherapy and Alcoholism . Bobbs-Merrill . New York . 1967 . 407–426.
  171. Book: Ditman KS, Bailey JJ . Evaluating LSD as a psychotherapeutic agent . Hoffer A . A program for the treatment of alcoholism: LSD, malvaria, and nicotinic acid . 353–402.
  172. Book: Schou N . Orange Sunshine: The Brotherhood of Eternal Love and Its Quest to Spread Peace, Love, and Acid to the World . 2010 . Thomas Dunne Books . registration . 9780312551834.
  173. Book: Jarnow J . Heads: A Biography of Psychedelic America . 2016 . Da Capo Press . 9780306822551.
  174. Microgram Bulletin . October 2005 . United States Drug Enforcement Administration . 38 . 10 . LSD Blotter Acid Mimic Containing 4-Bromo-2,5-dimethoxy-amphetamine (DOB) Seized Near Burns, Oregon . August 20, 2009 . https://web.archive.org/web/20121018052304/http://www.justice.gov/dea/pr/micrograms/2005/mg1005.pdf . October 18, 2012.
  175. Microgram Bulletin . November 2006 . 39 . 11 . United States Drug Enforcement Administration . 136 . Intelligence Alert – Blotter Acid Mimics (Containing 4-Bromo-2,5-Dimethoxy-Amphetamine (DOB)) in Concord, California . August 20, 2009 . https://web.archive.org/web/20121018052155/http://www.justice.gov/dea/pr/micrograms/2006/mg1106.pdf . October 18, 2012.
  176. Microgram Bulletin . March 2008 . 41 . 3 . United States Drug Enforcement Administration . Unusual "Rice Krispie Treat"-Like Balls Containing Psilocybe Mushroom Parts in Warren County, Missouri . August 20, 2009 . https://web.archive.org/web/20121017234315/http://www.justice.gov/dea/pr/micrograms/2008/mg0308.pdf . October 17, 2012.
  177. Web site: Iversen L . Temporary Class Drug Order Report on 5-6APB and NBOMe compounds . Advisory Council on the Misuse of Drugs . Gov.Uk . June 16, 2013 . May 29, 2013 . 14 . live . https://web.archive.org/web/20130921234700/https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/204808/J_TCDO_report_on_5-6APB_and_NBOMe_compounds.pdf. September 21, 2013.
  178. Microgram Bulletin . March 2009 . 42 . 3 . United States Drug Enforcement Administration . "Spice" – Plant Material(s) Laced With Synthetic Cannabinoids or Cannabinoid Mimicking Compounds . August 20, 2009 . https://web.archive.org/web/20120118165818/http://www.justice.gov/dea/programs/forensicsci/microgram/mg0309/mg0309.html . January 18, 2012.
  179. Microgram Bulletin . November 2005 . 38 . 11 . United States Drug Enforcement Administration . Bulk Marijuana in Hazardous Packaging in Chicago, Illinois . August 20, 2009 . https://web.archive.org/web/20121018052300/http://www.justice.gov/dea/pr/micrograms/2005/mg1105.pdf . October 18, 2012.
  180. Microgram Bulletin . December 2007 . 40 . 12 . United States Drug Enforcement Administration . SMALL HEROIN DISKS NEAR GREENSBORO, GEORGIA . August 20, 2009 . https://web.archive.org/web/20121017234332/http://www.justice.gov/dea/pr/micrograms/2007/mg1207.pdf . October 17, 2012.
  181. Web site: 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths . Erowid . February 28, 2016 . Erowid . live . https://web.archive.org/web/20160305193143/https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml . March 5, 2016.
  182. News: Hastings D . New drug N-bomb hits the street, terrifying parents, troubling cops . May 7, 2013 . New York Daily News . May 6, 2013 . live. https://web.archive.org/web/20130510103039/http://www.nydailynews.com/news/national/new-synthetic-hallucinogen-n-bomb-killing-users-cops-article-1.1336327. May 10, 2013.
  183. News: Feehan C . Powerful N-Bomb drug – responsible for spate of deaths internationally – responsible for hospitalisation of six in Cork . January 22, 2016. Irish Independent. January 21, 2016 . April 12, 2019. https://web.archive.org/web/20190412203933/https://www.independent.ie/irish-news/powerful-nbomb-drug-responsible-for-spate-of-deaths-internationally-responsible-for-hospitalisation-of-six-in-cork-34384507.html. live.
  184. Web site: Iversen L . Temporary Class Drug Order Report on 5-6APB and NBOMe compounds . Advisory Council on the Misuse of Drugs . Gov.Uk . June 16, 2013 . May 29, 2013 . live . https://web.archive.org/web/20130921234700/https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/204808/J_TCDO_report_on_5-6APB_and_NBOMe_compounds.pdf . September 21, 2013.
  185. Dyck E . 1965 . Flashback: Psychiatric Experimentation with LSD in Historical Perspective. . Canadian Journal of Psychiatry . 50 . 7.
  186. Web site: The Albert Hofmann Foundation . September 27, 2007 . Hofmann Foundation . https://web.archive.org/web/20190719174636/http://www.hofmann.org/ . July 19, 2019.
  187. Web site: LSD-Assisted Psychotherapy . MAPS . October 16, 2013. deviated . https://web.archive.org/web/20180511060129/http://www.maps.org/research/psilo-lsd. May 11, 2018.
  188. Bogenschutz MP . March 2013 . Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin . Current Drug Abuse Reviews . 6 . 1 . 17–29 . 23627783 . 10.2174/15733998113099990002.
  189. Web site: Jarow . Oshan . 2024-05-15 . Psychedelics could treat some of the worst chronic pain in the world . 2024-05-25 . Vox . en-US . May 25, 2024 . https://web.archive.org/web/20240525084603/https://www.vox.com/future-perfect/2024/5/15/24156372/psychedelics-chronic-pain-cluster-headache-medicine-lsd-psilocybin . live .
  190. Web site: RFA-AG-25-004: Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required) . 2024-05-25 . grants.nih.gov . May 25, 2024 . https://web.archive.org/web/20240525084606/https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-004.html . live .
  191. LSD Therapy for Persons Suffering From Major Depression - Full Text View . 2021-03-09 . ClinicalTrials.gov . February 8, 2021 . en . June 11, 2021 . https://web.archive.org/web/20210611214216/https://clinicaltrials.gov/ct2/show/NCT03866252 . live.
  192. Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials . Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M . 32038315 . 6985449 . Frontiers in Psychiatry . 10.3389/fpsyt.2019.00943 . 10 . January 2020 . 943 . free.
  193. Calder AE, Hasler G . Towards an understanding of psychedelic-induced neuroplasticity . Neuropsychopharmacology . 48 . 1 . 104–112 . January 2023 . 36123427 . 9700802 . 10.1038/s41386-022-01389-z . free.
  194. Olson DE . Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity . Biochemistry . 61 . 3 . 127–136 . February 2022 . 35060714 . 9004607 . 10.1021/acs.biochem.1c00812.
  195. Cohen, S. (1959). "The therapeutic potential of LSD-25". A Pharmacologic Approach to the Study of the Mind, p. 251–258.
  196. Use of d-Lysergic Acid Diethylamide in the Treatment of Alcoholism . Q. J. Stud. Alcohol . 20 . 577–590 . Chwelos N, Blewett DB, Smith CM, Hoffer A . 1959 . 3 . 10.15288/qjsa.1959.20.577 . 13810249 . June 20, 2012 . https://web.archive.org/web/20210224135151/https://www.erowid.org/references/texts/show/1852docid1733 . February 24, 2021 . live. Via Web site: Abstract . February 22, 2012 . live . https://web.archive.org/web/20120203022019/http://www.hofmann.org/papers/blewett_1.html . February 3, 2012 . Hofmann.org.
  197. Frood A . 2012-03-09 . LSD helps to treat alcoholism . Nature News . 10.1038/nature.2012.10200 . 137367650 . December 25, 2020 . March 8, 2021 . https://web.archive.org/web/20210308135250/https://www.nature.com/news/lsd-helps-to-treat-alcoholism-1.10200 . live.
  198. Vollenweider FX, Kometer M . The neurobiology of psychedelic drugs: implications for the treatment of mood disorders . Nature Reviews. Neuroscience . 11 . 9 . 642–51 . September 2010 . 20717121 . 10.1038/nrn2884 . 16588263.
  199. Baumeister D, Barnes G, Giaroli G, Tracy D . Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles . Therapeutic Advances in Psychopharmacology . 4 . 4 . 156–69 . August 2014 . 25083275 . 4104707 . 10.1177/2045125314527985.
  200. Liechti ME . Modern Clinical Research on LSD . Neuropsychopharmacology . 42 . 11 . 2114–2127 . October 2017 . 28447622 . 5603820 . 10.1038/npp.2017.86.
  201. News: Psychedelics are transforming the way we understand depression and its treatment . April 20, 2021 . The Guardian . Carhart-Harris R . 16 May 2021 . https://web.archive.org/web/20210611212734/https://www.theguardian.com/commentisfree/2021/apr/20/psychedelics-depression-treatment-psychiatry-psilocybin?utm_term=6ab4fa802d5ac7404da3d7218f1d1f2a&utm_campaign=GuardianTodayUS&utm_source=esp&utm_medium=Email&CMP=GTUS_email . June 11, 2021. live.
  202. Web site: Terry . Ken . 2024-03-26 . FDA Opens the Door to Clinical Use of LSD . 2024-05-25 . WebMD . en . May 25, 2024 . https://web.archive.org/web/20240525075810/https://www.webmd.com/mental-health/news/20240326/fda-opens-the-door-clinical-use-lsd . live .
  203. Sessa B . Is it time to revisit the role of psychedelic drugs in enhancing human creativity? . Journal of Psychopharmacology . 22 . 8 . 821–827 . November 2008 . 18562421 . 1908638 . 10.1177/0269881108091597.
  204. Janiger O, Dobkin de Rios M . LSD and creativity . Journal of Psychoactive Drugs . 21 . 1 . 129–134 . 1989 . 2723891 . 10.1080/02791072.1989.10472150 . https://web.archive.org/web/20091003005533/http://www.erowid.org/culture/characters/janiger_oscar/janiger_oscar.shtml . October 3, 2009 . live.
  205. Book: LSD, the problem-solving psychedelic . Stafford PG, Golightly BH . 1967 . live . https://web.archive.org/web/20120417105503/http://www.psychedelic-library.org//staf3.htm . April 17, 2012.
  206. Web site: Scientific Problem Solving with Psychedelics – James Fadiman . . May 29, 2013 . 2023-05-02 . en . September 8, 2019 . https://web.archive.org/web/20190908090741/https://www.youtube.com/watch?v=KtL5fafpRKc . live .
  207. Book: Fadiman J . The psychedelic explorer's guide : safe, therapeutic, and sacred journeys . 2018 . Tantor Media . 978-1-9773-7476-9 . 1031461623.
  208. News: Psychiater Gasser bricht sein Schweigen. July 28, 2009 . Basler Zeitung. June 19, 2011. https://web.archive.org/web/20111006122541/http://bazonline.ch/wissen/medizin-und-psychologie/Psychiater-Gasser-bricht-sein-Schweigen/story/25732295. October 6, 2011.
  209. Psychedelics promote structural and functional neural plasticity . Cell Reports . Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE . 2018 . 23 . 11 . 3170–3182 . 10.1016/j.celrep.2018.05.022 . 29898390 . 6082376 .
  210. News: Dolan EW . 2022-08-11 . Neuroscience research suggests LSD might enhance learning and memory by promoting brain plasticity . 2022-09-12 . Psypost - Psychology News . en-US . August 26, 2022 . https://web.archive.org/web/20220826005449/https://www.psypost.org/2022/08/neuroscience-research-suggests-lsd-might-enhance-learning-and-memory-by-promoting-brain-plasticity-63701 . live .
  211. Whelan A, Johnson MI . Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? . Pain Management . 8 . 3 . 217–229 . May 2018 . 29722608 . 10.2217/pmt-2017-0068 . 19160293 . August 22, 2020 . October 8, 2020 . https://web.archive.org/web/20201008201515/http://eprints.leedsbeckett.ac.uk/4843/1/LysergicAcidDiethylamide%28LSD%29andPsilocybinAM-JOHNSON.pdf . live.
  212. Web site: Famous LSD users . The Good Drugs Guide . 2008-10-20 . live . https://web.archive.org/web/20081007023344/http://www.thegooddrugsguide.com/articles/famous_users/lsd.htm . October 7, 2008.
  213. Web site: People on psychedelics . 2012-11-01 . live . https://web.archive.org/web/20130421145334/http://popwiki.net/ . April 21, 2013.
  214. Mason D . Review: Awe for Auden . The Hudson Review . 68 . 3 . Autumn 2015 . 492–500 . The Hudson Review, Inc. .
  215. Web site: W. H. Auden at Swathmore; An hour of questions and answers with Auden . Auden WH . 15 November 1971 . Exhibition notes from the W.H. Auden Collection . the Swarthmore College Library . February 23, 2021 . June 11, 2021 . https://web.archive.org/web/20210611212901/http://www.swarthmore.edu/library/auden/QandA_pt6.html . live .
  216. News: A Master of Memorable speech . MacMonagle N . The Irish Times . 17 February 2007 .
  217. Web site: Meyer A . 2022-01-24 . Daniel Ellsberg Talks Psychedelics, Consciousness and World Peace . 2022-01-29. Lucid News. en-US. January 29, 2022. https://web.archive.org/web/20220129143452/https://www.lucid.news/daniel-ellsberg-talks-psychedelics-consciousness-and-world-peace/. live.
  218. Book: Feynman RP . Surely You're Joking, Mr. Feynman!: Adventures of a Curious Character . Leighton R . . 1985 . 978-0-393-01921-6 . 10925248. Surely You're Joking, Mr. Feynman! .
  219. Book: Gleick J . James Gleick . Genius: The Life and Science of Richard Feynman . . 1992. 978-0-679-40836-9 . 243743850.
  220. Web site: Q&A with Jerry Garcia: Portrait of an Artist as a Tripper . Relix Magazine . April 20, 2010 . 2013-06-29 . Alderson J . https://web.archive.org/web/20100521033451/http://www.relix.com/features/2010/04/20/q-a-with-jerry-garcia-portrait-of-an-artist-as-a-tripper?3 . May 21, 2010.
  221. The Bill Gates Interview . Playboy . July 1994 . https://web.archive.org/web/20140707190401/http://www.playboy.com/playground/view/50-years-of-the-playboy-interview-bill-gates . July 7, 2014.
  222. News: Colman D . Aldous Huxley's LSD Death Trip . Open Culture . October 2011 . 1 November 2011 . live . https://web.archive.org/web/20111112140024/http://www.openculture.com/2011/10/aldous_huxleys_lsd_death_trip.html . November 12, 2011.
  223. News: Bosker B . The Steve Jobs Reading List: The Books And Artists That Made The Man . Huffington Post . 23 October 2011 . 21 October 2011 . live . https://web.archive.org/web/20111022123850/http://www.huffingtonpost.com/2011/10/21/the-steve-jobs-reading-list-the-books_n_1024021.html . October 22, 2011.
  224. Web site: LSD, My Problem Child · Radiance from Ernst Junger. www.psychedelic-library.org . April 17, 2021. May 12, 2021. https://web.archive.org/web/20210512173700/http://www.psychedelic-library.org/child7.htm. live.
  225. Web site: 1998-02-15 . Is 'Lucy in the Sky with Diamonds' Code for LSD? . 2012-06-20 . Snopes.com . December 20, 2021 . https://web.archive.org/web/20211220152957/https://www.snopes.com/fact-check/lucy-in-the-sky-with-diamonds/ . live .
  226. The Truth Behind "LSD" . Matus V . June 2004 . The Weekly Standard . November 3, 2019 . live . March 8, 2021 . https://web.archive.org/web/20210308185326/https://www.washingtonexaminer.com/weekly-standard/the-truth-behind-lsd.
  227. Web site: When Michel Foucault Tripped on Acid in Death Valley and Called It "The Greatest Experience of My Life". September 1975. Open Culture. en-US. 2019-04-27. March 15, 2021. https://web.archive.org/web/20210315225234/https://openculture.com/2017/09/when-michel-foucault-tripped-on-acid-in-death-valley-and-called-it-the-greatest-experience-of-my-life-1975.html. live.
  228. Web site: Blowing The Philosopher's Fuses: Michel Foucault's LSD Trip in The Valley of Death. Penner J. Los Angeles Review of Books. June 17, 2019 . en-US. 11 April 2021. April 11, 2021. https://web.archive.org/web/20210411165642/https://lareviewofbooks.org/article/blowing-the-philosophers-fuses-michel-foucaults-lsd-trip-in-the-valley-of-death/#_ftnref4. live. Wade: "We fell silent to listen to Stockhausen's Songs of Youth. Zabriskie Point was filled with the sound of a kindergarten playground overlaid with electric tonalities. Kontakte followed. Glissandos bounced off the stars, which glowed like incandescent pinballs. Foucault turned to Michael and said this is the first time he really understood what Stockhausen had achieved".
  229. Book: Foucault in California: [A True Story-–Wherein the Great French Philosopher Drops Acid in the Valley of Death]. Wade S . Heyday Books . 2019 . 9781597144636. In a letter to Wade, dated 16 September 1978, Foucault authorised the book's publication and added: "How could I not love you?"
  230. LSD: The Geek's Wonder Drug? . 2008-03-11 . Harrison A . 2006-01-16 . Wired . Like Herbert, many scientists and engineers also report heightened states of creativity while using LSD. During a press conference on Friday, Hofmann revealed that he was told by Nobel-prize-winning chemist Kary Mullis that LSD had helped him develop the polymerase chain reaction that helps amplify specific DNA sequences. . live . https://web.archive.org/web/20080505100508/http://www.wired.com/science/discoveries/news/2006/01/70015 . May 5, 2008.
  231. Web site: Higgins C. 2018-04-14. 'There is no such thing as past or future': physicist Carlo Rovelli on changing how we think about time . The Guardian . 2022-02-06. January 11, 2022. https://web.archive.org/web/20220111094136/https://www.theguardian.com/books/2018/apr/14/carlo-rovelli-exploding-commonsense-notions-order-of-time-interview. live.
  232. Book: Sacks O . 2012 . Hallucinations . . 106 . 978-0-307-94743-7 . On the West Coast in the early 1960s LSD and morning glory seeds were readily available, so I sampled those, too. . June 30, 2018 . live . April 21, 2021 . https://web.archive.org/web/20210421064209/https://www.oliversacks.com/books-by-oliver-sacks/hallucinations/.
  233. Web site: Bose SD . When Trey Parker and Matt Stone went to the Oscars on LSD Swapnil Dhruv Bose . December 27, 2021 . FarOutMagazine.co.uk . January 20, 2022 . live . January 20, 2022 . https://web.archive.org/web/20220120001258/https://faroutmagazine.co.uk/when-trey-parker-and-matt-stone-went-to-the-oscars-on-lsd/.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "LSD".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.